UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10

Amendment No. 5

GENERAL FORM FOR REGISTRATION OF SECURITIES

UNDER SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 333-168527

CANNAPOWDER, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Nevada	20-3353835
(State of Incorporation)	(I.R.S. Employer Identification No.)
20 Raoul Wallenberg Street, Tel Aviv, Israel	6971916
(Address of Principal Executive Offices)	(ZIP Code)

Registrant’s Telephone Number, Including Area Code: +972-3-613-0421

Securities to be registered under Section 12(b) of the Act: None

Securities to be registered under Section 12(g) of the Exchange Act: Common stock; $0.0001 par value

(Title of Class)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act) or a smaller reporting company.

Large accelerated filer [  ] Accelerated filer [  ] Non-Accelerated filer [  ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

TABLE OF CONTENTS

Item 1.	Business	3
Item 1A.	Risk Factors	13
Item 2.	Financial Information	19
Item 3.	Properties	22
Item 4.	Security Ownership of Certain Beneficial Owners and Management	22
Item 5.	Director, Executive Officers and Key Employees	23
Item 6.	Executive Compensation	25
Item 7.	Certain Relationships and Related Transactions, and Director Independence	26
Item 8.	Legal Proceedings	26
Item 9.	Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters	26
Item 10.	Recent Sales of Unregistered Securities	27
Item 11.	Description of Registrant’s Securities to be Registered	27
Item 12.	Indemnification of Officers and Directors	30
Item 13.	Financial Statements and Supplementary Data	30
Item 14.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	30
Item 15.	Financial Statements and Exhibits	30

2

PART I

ITEM 1. DESCRIPTION OF BUSINESS

Background and Former Operations

CannaPowder, Inc., f/k/a Smart Energy Solutions, Inc. (the “Company” or “Registrant”) was incorporated in 1999 in the State of Utah under the name Datigen.com, Inc. On August 25, 2005, the Registrant was redomiciled from Utah to Nevada pursuant to a merger with and into its wholly-owned subsidiary, Smart Energy Solutions, Inc., a Nevada corporation and, in connection therewith, its name was changed to Smart Energy Solutions, Inc.

Prior to the merger into its wholly-owned subsidiary, the Company was engaged in activities including development and marketing of various internet and internet related products and services, investment in real property related instruments, and providing concrete cutting and finishing services to construction sites seeking to comply with certain provisions of the American Disability Act of 1991. In November 2004, the Company had a change in control as a result of the purchase of a majority of the Company’s outstanding common stock by unaffiliated individuals.

In connection with the change in control, the Company determined to pursue other business opportunities and, as a result, on March 23, 2005, the Company entered into an asset purchase agreement with Purisys, Inc., a New Jersey corporation, and acquired the intellectual property rights and certain other assets relating to a product known as the “Battery Brain,” a device attached to a motor vehicle battery for the purpose of protecting the vehicle from battery failure and theft.

Following the purchase of the Battery Brain assets, the Company devoted its resources and entered into agreements with third parties for the manufacture and distribution of products using the Battery Brain technology. During the period from March 2005, the date of the asset purchase agreement, through the end of 2009, the Company devoted its efforts to marketing activities directed at the automotive industry, including automotive retail, dealers, OEMs, and automotive specialty such as fleets, military, heavy trucks and equipment, motor home/RV and marine.

3

The Company continued to generate losses from operations and, as of its fiscal year-ended December 31, 2008, the Company had an accumulated deficit of in excess of $22 million. While the Company continued to file reports under the Securities Exchange Act of 1934 (the “Exchange Act”) through its quarterly report on Form 10-Q for the period ended September 30, 2009, the Company lacked sufficient capital resources to continue to fund the expenses including professional fees associated with being a current, reporting company under the Exchange Act.

As a result, from and after the filing of its 10-Q for the period ended September 30, 2009, the Company ceased active business operations and determined to devote its limited and depleting cash resources to seek operations that would generate revenues and positive cash flow compared to its prior operations seeking to exploit its Battery Brain technology. The Company became delinquent in its reporting obligations under the Exchange Act, failing to file its annual report on Form 10-K for the year ended December 31, 2009 and continued to be a delinquent filer until it filed a Form 15, terminating its registration under Section 12(g) of the Exchange Act on July 24, 2013.

Prior to filing the Form 15, the Company’s assets became subject to a proceeding before the Superior Court of the State of New Jersey, which resulted in the appointment of a receiver in early 2013. The principal creditor in that proceeding was Aharon Levinas, who had sold the Battery Brain assets formerly owned by Purysis in March 2005. On June 7, 2013, in connection with the order of the Superior Court of the State of New Jersey, the Court authorized and approved the sale, transfer and assignment of all of the Company’s assets to Aharon Levinas, free and clear of any liens, claims or encumbrances and granting Mr. Levinas effective control of the Company.

During November 2014 and March 2015, third-party investors acquired control of the Company by purchasing a control block of shares each holding 137,500 shares representing 88% of the Company’s issued and outstanding shares of common stock. Reference is made to the disclosure under “Item 4. Security Ownership of Certain Beneficial Owners and Management.”

Recent Corporate Developments

On August 30, 2017, a new wholly-owned subsidiary was registered in Israel under the name of Canna Powder Ltd. (“CannaPowder Israel” or the “Subsidiary”), with 100 common shares outstanding (the “Subsidiary Shares”), all of which were held in escrow on behalf of the Company by Israel attorney, Alon Nave. On September 27, 2017, pursuant to board resolution, the 100 Subsidiary Shares held in escrow were transferred to the Company.

The Subsidiary’s management includes Lavi Krasney, its CEO, and Rafi Ezra, its CTO. Reference is made to the disclosure under the subcaption “Key Employees” included in “Item 5. Directors and Executive Officers” below.

Development is being conducted at the Hebrew University under the supervision of the inventor of the technology, Professor Shlomo Magdassi, pursuant to the term of the Feasibility Study and Option Agreement dated September 14, 2017 (the “Feasibility Study”), a fully-executed copy of which is attached as Exhibit 10.1.2 to this Form 10 amendment, as more fully discussed below.

On December 27, 2017, a board resolution was adopted to issue an additional: (i) 800 Subsidiary Shares to the Company; and an additional 100 Subsidiary Shares to Rafi Ezra and, as a result, effective December 27, 2017, Canna Powder Ltd became a 90% owned subsidiary of the Company and a minority interest of 10% owned by Rafi Ezra.

In anticipation of the formation of CannaPowder Ltd, the Company’s newly organized Israeli subsidiary, the Company began to raise capital through the private sale of its equity securities primarily pursuant to the exemptions provided under Regulation S promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Act”) and, to a lesser extent, pursuant to Regulation D promulgated by the SEC under the Act (collectively, the “Equity Raise”). To date, the Company has raised approximately $1,226,900 in the Equity Raise. Reference is made to the disclosure under “Item 10. Recent Sales of Equity Securities” and “Note (7) Subsequent Events” in the Notes to Consolidated Financial Statements, below.

4

The Equity Raise by the Company was and continues to be for the purpose of funding the Company’s business involving its development program to establish cannabis powder production facilities utilizing the proprietary, licensed technology as more fully-described under “Intellectual Property” below (the “Development Program”). Pursuant to the Company’s Development Program, we expect to have product formulation and testing completed in 2020, pre-clinical studies commencing in 2021, first human and safety trials in 2022 and efficacy trials in 2023. Reference is made to the disclosure under the “The FDA Approval Process” below. As a result, unless we are able to expedite the above timetable, of which there can be no assurance, the earliest that we can expect to begin commercial sales will be 2023. In fact, there can be no assurance that the Development Program will be successfully implemented within our expected timeline notwithstanding the Company’s success in its Equity Raise to date, nor can there be assurance that the Company may not require additional capital to fully implement its business plan and complete production of commercially viable products based on its technology which is the subject of the Feasibility Study discussed below under “Planned Research and Development and Current Trends.” Reference is also made to Appendix B-1 attached to the License Agreement filed as an exhibit to our Form 8-K filed with the SEC on May 25, 2018. Reference is also made to the fully-executed copy of the License Agreement, attached at exhibit 10.2.2 hereto.

If and when we reach the commercial stage, of which there can be no assurance, the Company’s plan is to establish and operate several production facilities to be located in countries/territories determined by the Company according to their size and provided that the applicable regulatory environment that permits studies applicable to other activities prerequisite to commercial exploitation of medical cannabis generally and the Company’s plan to develop cannabis-based powders for medical uses. The Company believes that it will be able to produce cannabis powders for medical uses at a cost advantage. Notwithstanding our belief in our ability to produce cannabis powders for medical uses at a cost advantage, in fact, to date we have not produced and cannabis powders for medical or any other uses and there can be no assurance that: (i) we will ever be able to produce commercially viable cannabis powders for medical uses; (ii) any cannabis we produce, either alone or in collaboration with third parties, will be accepted by the medical community, either in Israel or anywhere else in the world; (iii) any cannabis powders will be produced at a cost advantage; or (iv) we will be able to successfully compete with established companies in the medical cannabis industry, virtually all of which have far longer operating histories and far greater capital resources.

Planned Research and Development and Current Trends

We believe that there has been an increasing recognition amongst medical professionals conducting research in hospitals, including leading hospitals in Israel such as Hebrew University, Jerusalem, Israel and Sheba Academic Medical Center located in Tel Hashomer, Israel, among others, that the therapeutic effect of medical cannabis is due to the total number of cannabinoids working together. There is a scientific effort currently being conducted in Israel, as well as other countries, to analyze and understand how the various components within cannabis work, including ongoing scientific studies to develop separate medical components for use in treatment of different medical conditions using various components or combinations for each cannabinoid. Nevertheless, the laws of the United States presently do not permit studies to be conducted in hospitals in the U.S. notwithstanding approval of medical and recreation cannabis in 29 of the 50 states.

The aim of CannaPowder Israel is to identify the active pharmaceutical ingredient (API) and to endeavor to understand the cannabidiol (CBD) and tetrahydrocannabinol (THC) content of each product. Researchers, principally in Israel, have discovered approximately in excess of 100 cannabinoids, chemical compounds unique to the cannabis plant. The most common are CBD, cannabinol (CBN) and THC. CBN and THC interact with CB1 and CB2 receptors, which are located throughout the human body. CB1 receptors are primarily located in the brain and central nervous system. CB2 receptors are located throughout the body including the gastrointestinal and urinary tracts that are responsible for regulating neurotransmission. The CB1 and CB2 receptors help control bodily reactions such as inflammation and pain, which are areas are of great therapeutic interest with respect to drug development. Identifying cannabinoid receptors and the compounds that interact with them has helped accelerate clinical investigations of cannabinoid-based drugs. To date, due to the challenges of researching plant-derived cannabinoids in the United States, most U.S. research has been conducted utilizing synthetically produced cannabinoids, which as chemical compounds, are chemically identical to plant-derived cannabinoids.

5

The FDA Approval Process

We believe cannabinoid-based drugs using the powders we plan on developing may be able to provide a treatment model for patients suffering from certain diseases, disorders and medical conditions. However, at present, because of U.S. Food and Drug Administration (“FDA”) and Drug Enforcement Administration (“DEA”) restrictions, most companies involved in research and development of cannabinoid therapeutic applications, especially in the United States, currently use synthetics. Furthermore, our subsidiary, Canna Powder Israel, has not yet even commenced any of the following:

(i) New Drug Application known as an NDA: The regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization.  The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.  The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA. The goals of the NDA are to provide enough information to permit the FDA staff to reach the following key decisions:

● Whether the drug is safe and effective in its proposed use(s), and whether the benefits of the drug outweigh the risks;

● Whether the drug's proposed labeling (package insert) is appropriate, and what it should contain; and

● Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity.

The documentation required in an NDA is supposed to tell the drug's whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged. 

(ii) Investigational New Drug Application (IND): An Investigational New Drug Application (IND) is a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is not the subject of an approved new drug application. Drug developers, or sponsors, must submit an Investigational New Drug (IND) application to FDA before beginning clinical research. In the IND application, developers must include:

● Animal study data and toxicity (side effects that cause great harm) data;

● Manufacturing information;

● Clinical protocols (study plans) for studies to be conducted;

● Data from any prior human research; and

● Information about the investigator.

The initial IND submission and each subsequent submission to the IND should be accompanied by a variety of information and attachments sent by the Sponsor-Investigator [in this case either by the Company or its Chief Medical Officer] to FDA, which information can be supplied in the form of curriculum vitae, rather than entering that information directly onto the form. The Food and Drug Administration Amendments Act of 2007, enacted on September 27, 2007, added new Section 402(j) to the Public Health Service Act and expanded the current database known as ClinicalTrials.gov to include mandatory registration and reporting of results for applicable clinical trials of human drugs (including biological products) and devices.

FDA regulations further require that, at the time of submission of an application, including an Investigational New Drug application (IND), the application must be accompanied by a certification that all applicable requirements have been met. Where available, such certification must include the appropriate National Clinical Trial (NCT) to comply with the certification requirement to determine whether the requirements of that subsection apply to any clinical trial(s) referenced in an IND application. Upon receipt of the IND by FDA, an IND number will be assigned, and the application will be forwarded to the appropriate reviewing division. The reviewing division will send a letter to the Sponsor-Investigator providing notification of the IND number assigned, date of receipt of the original application, address where future submissions to the IND should be sent, and the name and telephone number of the FDA person to whom questions about the application should be directed. Studies shall not be initiated until 30 days after the date of receipt of the IND by FDA unless you receive earlier notification by FDA that studies may begin.

(iii) Phase I, II and III Trials/Studies: Clinical trials follow a typical series from early, small-scale, Phase 1 studies to late-stage, large scale, Phase 3 studies. While preclinical research answers basic questions about a drug’s safety, it is not a substitute for studies of ways the drug will interact with the human body. “Clinical research” refers to studies, or trials, that are done in people. As the developers design the clinical study, they will consider what they want to accomplish for each of the different Clinical Research Phases and begin the Investigational New Drug Process (IND), a process they must go through before clinical research begins.

Designing Clinical Trials: Researchers design clinical trials to answer specific research questions related to a medical product (such as the Company’s planned cannabis-based powders for medical treatments. These trials follow a specific study plan, called a protocol, that is developed by the researcher or manufacturer. Before a clinical trial begins, researchers review prior information about the drug to develop research questions and objectives. Then, they decide:

● Who qualifies to participate (selection criteria);

● How many people will be part of the study;

● How long the study will last;

● Whether there will be a control group and other ways to limit research bias;

● How the drug will be given to patients and at what dosage;

● What assessments will be conducted, when, and what data will be collected; and

● How the data will be reviewed and analyzed.

6

Clinical trials follow a typical series from early, small-scale, Phase 1 studies to late-stage, large scale, Phase 3 studies.

Phase I:

Phase 1 Study Participants: 20 to 100 healthy volunteers or people with the disease/condition. The length of the Phase I Study can last several months, and the purpose is to determine safety and dosage. according to the FDA publications referenced below, approximately 70% of drugs move to Phase II.

https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm#collapse1

Phase II: Phase II involves study participants of up to several hundred people with the disease/condition and the length of Phase II Study can range from several months to 2 years. The purpose of the Phase II Study is to determine efficacy and side effects. Depending upon the results of the efficacy and side effects studies, approximately 33% of drugs move to the next phase which is Phase III according to the FDA publication cited below.

https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm#collapse1

Phase III: Phase III typically involves study participants of 300 to up to 3000 volunteers and this Phase III can last from 1 to 4 years. The purpose of Phase III studies is to further determine efficacy and monitoring adverse reactions.

As discussed more fully above, we have not yet prepared an NDA or IND for submission to the FDA nor conducted any activities in contemplation for Phase I, Phase II or Phase III Studies/T rials . All of the foregoing are prerequisite to any approvals by the FDA, of which there can be no assurance. In fact, we are still in the research and development stage and do not have any cannabis powder-based products ready for preclinical development, filing of an IND or for any phase I trials, phase II trials or phase III trials. As a result, we have no actual basis for our belief that powders can provide a suitable much less a potentially more advantageous treatment or means of administration of medical cannabis for patients.

While we believe that there may be a rising demand for cannabinoid-derived drugs that may be driven by favorable changes in legislation and demographic factors, among other factors in more states within the U.S., over which we have no control and upon which we will remain wholly-dependent, there can be no assurance that demand will rise or that the U.S. federal government may not become more hostile to the actions of individual states that have approved or are contemplating approval of medical or recreation cannabis.

Controlled substance laws differ between countries and legislation in certain countries may restrict or limit our ability to distribute our cannabis-based powders, if and when developed, for use and sale as commercially viable and efficacious medical treatments. Nevertheless, we believe that the U.S. can potentially represent a major market for cannabis-based drug candidates, if the regulatory conditions remain favorable in an increasing number of states, provided that the U.S. federal government does not take enforcement action to restrict or halt use of medical cannabis in those states where it is presently legal. There can be no assurance that action by the U.S. government at the federal level may not occur or if the Company’s ability to achieve commercial success, if any, in one or more states where medical cannabis is currently legal will not be adversely impacted. Furthermore, as a pre-development stage company, there can be no assurance that our cannabis-based medical powders, if and when developed, will prove to be commercially viable and/or efficacious.

Within the European Community (EU), medical cannabis program regulatory frameworks currently exist in countries, including the Netherlands, Italy, Germany, Finland, Norway, Ukraine, Estonia, Switzerland and the Czech Republic. It is also anticipated that there may well be positive policy changes in many member countries of the European Union regarding the medical use of cannabis and cannabinoid-derived drugs. However, there can be no assurance that a positive regulatory environment will continue or expand within the EU. In addition, medical cannabis has been decriminalized in Russia, Mexico, Columbia, Uruguay, Paraguay and Colombia.

The objective of our subsidiary, Canna Powder Israel, is to develop nano-cannabis powder, standardized from cannabis oil in a known Cannanoid composition. Canna Powder Israel is in the process of licensing what it believes will represent a breakthrough platform technology in drug administration and with the view to applying it to enable the commercial production of cannabis powder.

The technology has been developed by scientists at the Hebrew University, Jerusalem, which technology has been licensed to the Company’s Israeli Subsidiary. On September 14, 2017, Canna Powder Israel entered into the above-referenced Feasibility Study with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), under the supervision of the inventor of the technology, Professor Shlomo Magdassi. A copy of the Feasibility Study is attached as Exhibit 10.1.2 hereto. The Company believes that this technology involves a new technique that should enable the preparation of nanoparticles from micro emulsions of active ingredients that can be stored as powders and then dissolved in water when required.

The management team of Canna Powder Israel, consisting of Lavi Krasney and Rafi Ezra, the CEO and CTO, respectively. Reference is made to the disclosure under “Item 5. Directors and Executive Officers; Key Employees” below. Our Subsidiary’s management, working in collaboration with the scientists at Hebrew University under the supervision of Professor Shlomo Magdassi, believe this technology may be adapted for many different insoluble drugs to provide enhanced dissolution properties and to improve solubility, bioavailability and storage properties and solutions. We base our belief that nanoparticles offer improved bioavailability in found in the attached published medical articles:

“Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability” by Yin J¹, Xiang C¹, Wang P¹, Yin Y², Hou Y³; Link: https://www.ncbi.nlm.nih.gov/pubmed/28435268, and “Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake” by Cho HJ¹, Park JW², Yoon IS², Kim DD³ Link: https://www.ncbi.nlm.nih.gov/pubmed/24531717

However, potential investors should be aware that there can be no assurance that the beliefs and expectations of our subsidiary’s management and the scientists as Hebrew University will be achieved, that cannabis powder-based drugs will be proven to be efficacious, that nanoparticles offer improved bioavailability and/or that any cannabis powder-based drugs will be commercially accepted or have any competitive or other advantages compared to other cannabis-based drugs and treatments currently in the market.

Our development program plan is to produce a platform technology for preparing dispersible powders or aqueous dispersions of nanoparticles of water-insoluble organic compounds by converting micro emulsions or nano-emulsions containing the active chemicals into powders. There can be no assurance that we will be successful or have the necessary capital, personnel and other resources to implement our development program.

7

The key features, we believe, will include:

● Preparation of the nano-emulsions with relatively simple and reproducible technologies, without the use of any special equipment.

● Can dilute the powders in water to obtain required concentration of active ingredient.

● Reduces dose of drug needed.

● Nanoparticles offer improved bioavailability and improved efficacy.

● Simple, cost effective technique.

● Powders have relatively long shelf life.

Although there can be no assurance as our technology has not been previously used to develop commercially-viable, cannabis powder-based drugs, we believe that our new technology should be well-suited to medical cannabis because it is based upon and deals specifically with oily/lipophilic materials which is exactly the form in which cannabis exists. Our plan is to be able to produce a micronized powder containing cannabinoids in a particle size of 100 nanometers, which we hope can be easily incorporated in a commercial product, such as a capsule, based upon our belief that this product will be the result of a pharmaceutical not a chemical process. Notwithstanding our belief, there can be no assurance that our development program will be successful in being able to produce a micronized powder containing cannabinoids in a particle size of 100 nanometers, or any other size, for that matter, and that any cannabis-based powders we produce will be commercially viable.

The process of producing the cannabis-based powders under our development program is intended to utilize high pressure emulsifying agents that we hope will vaporize water to particles, which evaporation process is expected to take only hours as opposed to days or weeks. If successful, of which there can be no assurance, this should be permit and facilitate a quicker and less expensive production process than existing processes for producing medical cannabis with consistent dosages. Furthermore, the production process should not be labor intensive or require a large and therefore costly facility, thereby providing the economic advantage of being able to produce commercial quantities of cannabis powder at costs far less than existing methods currently in use by other manufacturers of medical cannabis drugs and treatments. There can be no assurance that our expectations will reach fruition or that we will have sufficient capital or other resources to complete our development program in a timely manner, if at all. If and when we achieve the commercial stage, of which there can be no assurance.

Our plan is for Canna Powder Israel to establish and operate several production facilities, each located in countries and territories selected according to their size and favorable regulatory environment for medical cannabis. We have completed the basic formulation of the powder and the basic production process required to produce nano-powder out of Cannabis oil. The necessary steps for us to reach are to achieve a reproducible process which would result in a consistent yield and a stable powder with a practical shelf life. We currently plan to initially develop two products: (i) sublingual tablet; and (ii) dry powder for inhalation. Nevertheless, we have not yet reached a conclusion regarding the indications which these products would address. The expected costs are projected to be approximately $385,000 to $565,000 during the next 18 months. However, there can be no assurance that we will be successful in developing our new products within the projected time-frame and/or within the projected budget estimate. If we experience significant delays or cost overruns, our operations and plans could be materially adversely affected.

Our business plan is to establish the first production facility in Israel, which will be the Company’s pilot site for all our planned product development. We have identified a production site in Israel and we are currently in what we believe to be advanced negotiations with a third-party regarding the collaboration agreement which will also provide us with the use of facilities for production. If the negotiations are successfully concluded in a timely manner, we believe the site should be fully operational by the end of Q1 2019 and our subsidiary's production line should be ready 2-3 months afterwards. At present, we estimate that the costs of designing and readying the site to production capability should be approximately US$300,000 to $400,000. This is in addition to the expected product development costs that are projected to be approximately $385,000 to $565,000 during the next 18 months.

However, there can be no assurance that our negotiations with the third-party, or any other party for that matter, in a timely manner or otherwise, or that we will not experience costs in excess of our budget estimate. In addition, we will continue to be dependent upon the availability of capital resources and the regulatory environment in Israel, which is expected to be maintained at least at the present levels.

We contemplate that in the future, without any fixed timeframe, and subject to applicable regulatory conditions, to follow our Israeli site with one or more sites in the U.S., but only in those states where cannabis-based medical products are authorized for medicinal use and/or recreational use. However, at the date of this amended registration statement, we have not yet determined the specific states where we contemplate establishing production facilities, because the regulatory environment of Cannabis in the U.S. is continuing to evolve. Furthermore, to date we have not contacted any third-parties in the U.S. or commenced any negotiations with respect to any production sites in the U.S. nor have we established a budget estimate or any time table for commencing any such negotiations.

The Company also has very preliminary plans to establish one or more production sites in Canada and in Germany, both countries where medical cannabis is regulated but not subject to prohibition. Nevertheless, to date we have not contacted any third-parties in either Canada or Germany nor have we commenced any negotiations with respect to any production sites in either country. As a result, we have not established any budget estimates timetables for commencing any such negotiations in Canada or Germany. There can be no assurance that the existing regulatory environment in Canada or Germany will not change, which could adversely impact our plans.

The Medical Cannabis Market

Cannabis has been used for medicinal purposes for thousands of years and there is anecdotal evidence that cannabis may be an effective treatment for pain relief, inflammation and a number of other medical disorders. According to an IBIS World report, new medical research and changing public opinion have boosted industry growth. Nevertheless, there can be no assurance that any historical anecdotal evidence of the efficacy of medical cannabis, which the United States government has expressly rejected to date, will in fact boost industry growth generally or benefit the Company and is prospects specifically. Furthermore, conclusions regarding efficacy are within the sole authority of the FDA or similar foreign government entity, none of which have established or otherwise approved the efficacy of cannabis in the treatment of, among other conditions, severe or chronic pain, inflammation, nausea and vomiting, neurologic symptoms (including muscle spasticity), glaucoma, cancer, multiple sclerosis, post-traumatic stress disorder, anorexia, arthritis, Alzheimer’s, Crohn’s disease, fibromyalgia, ADD, ADHD, Tourette’s syndrome, spinal cord injury and numerous other conditions.

8

The global medical cannabis market is expected to grow significantly from $8,280.6 million in 2017 to $28,070.0 million in 2024, at a CAGR of 19.1%¹.

We believe that public awareness regarding the perceived medical benefits of cannabis by segments of the medical community as well as by a growing number of persons publicly, we believe, has led to a growing market in several countries and in those states in the U.S. where it is currently legal. There can be no assurance that this apparent growing perception will continue and/or result in greater acceptance of cannabis-based drugs generally or the Company’s planned cannabis powder-based drugs and therapies, if successfully developed.

Those manufacturers currently producing medical cannabis typically remove THC, the principal psychoactive compound which causes the well-known and recognized euphoria related hallucinations or even, what some define, as psychotic episodes on the negative spectrum of THC’s potential side effects. As a result, the cannabis-based medical products presently in the market then only contain various formulations of cannabidiol (CBD), a chemical compound which many believe provides health benefits, notwithstanding the contrary positions of the U.S. federal government and its agencies, the FDA and DEA. At present, many countries and 29 of 50 states in the U.S. permit the prescription and sale of medical cannabis to adults and although there appears to be a trend in the U.S. that additional states will approve medical cannabis, laws at the federal level in the U.S. still treat cannabis, whether for medical or recreational use, as a Class 1 Controlled Substance and illegal.

At present, cannabis is used widely in health foods and pet medicines. Health foods comprise juices, cannabis edibles, and drinkable medicines. For instance, Simply Pure, a U.S. based company, offers cannabis edibles and Auntie Dolores, another U.S. based company, manufactures CBD pet treats to relieve pets of anxiety and pain. Cannabis edibles are offered in the form of lozenges, breath strips, and gummies. In an attempt to propel market growth, Microsoft Azure has offered its Cloud services to industry participants for the sale of cannabis.

The global medical cannabis market is segmented according to applications and regions. Market applications comprise cancer, chronic pain, arthritis, migraine, and others. Chronic pain is the largest application segment due to a huge patient base. In 2017 it accounted for nearly 40% of global revenues². We believe that this is the result of an increasing number of clinical trials related to the use of medical cannabis in pain management. The use of cannabis to treat symptoms and side effects of cancer treatment is expected to grow at an 18.2% CAGR³ thru to 2025. Although, medical use of cannabis is considered illegal, many states I the U.S. are passing legislation to legalize it.

However, it is the well-known position of the U.S. government that cannabis in any formation has not yet received FDA approval for use in cancer or any other treatment, nor is any approval anticipated for the foreseeable future. This has adversely impacted and is expected to continue to limit any potential the growth of medical cannabis for the cancer application or any other segment, absent any positive results from clinical trials, of which we have no information and therefore cannot make any affirmative assertions and have no scientific evidence or support.

North America led the medical cannabis market with nearly 49% shares in 2015⁴. The region is supported by the legalization of cannabis in 29 of the 50 states of the U.S. as well as in Canada. However, prohibition of medical cannabis in most of Latin America and Asia has limited the growth of this market to Europe, North America, and other countries world-wide.

Prominent companies presently engaged in this field include: Cannabis Sativa, Inc.; United Cannabis Corporation; Growblox Sciences, Inc.; and GW Pharmaceuticals plc which is a UK pharmaceuticals manufacturer that has recently gained FDA approval of GW’s Epidiolex^®, a cannabidiol oral solution for the treatment of seizures associated with rare forms of epilepsy.

The forecast level of retail sales in the US of medical cannabis for the years 2013 to 2021 is shown in the table:

	2013		2014		2015		2016		2017		2018		2019		2020		2021
	$b		$b		$b		$b		$b		$b		$b		$b		$b
Minimum		1.6		1.6		2.0		2.2		2.5		2.9		3.1		3.7		4.8
Maximum		1.6		2.0		2.4		2.7		3.2		3.8		4.3		5.1		6.8

Source: Medical Marijuana in the US, Statista, 2018

9

Competition

We will face competition from larger companies that are or may be in the process of offering similar products to ours. Many of our current and potential future competitors have far longer operating histories, significantly greater financial, marketing and other resources than we may be expected to have for the foreseeable future and beyond.

Competitors may include major pharmaceutical and biotechnology companies and public and private research institutions. Management cannot be certain that we will be able to compete against current or future competitors or that competitive pressure will not seriously harm our business prospects. These competitors may be able to react to market changes, respond more rapidly to new regulations or allocate greater resources to the development and promotion of their products than we can.

Furthermore, some of these competitors may make acquisitions or establish collaborative relationships among themselves to increase their ability to rapidly gain market share. Large pharmaceutical companies may eventually enter and, as a likely result, dominate the market.

Given the rapid changes affecting the global, national, and regional economies in general and cannabis-related medical research and development in particular, we may not be able to create any perceived competitive advantage from our cannabis-based powder formulations in the marketplace if, indeed, we are successful in producing cannabis powder-based drugs and therapies.

Our success, of which there can be no assurance, will also depend on our ability to respond quickly to, among other things, changes in the economy, market conditions, and competitive pressures, as well as the availability of adequate capital resources to fund our development plan. Any failure to anticipate or respond adequately to such changes, or any insufficiency of capital resources as they are needed to implement our development plan would have a material effect on our financial condition, operating results, liquidity, cash flow and our operational performance.

Intellectual Property

At present, all of our research and development is conducted in Israel and is the subject of the feasibility study being conducted at Hebrew University, pursuant to the terms of a Feasibility Study between Canna Powder Israel and Yissum. To date, the Company has paid Yissum $30,000 in 3 monthly installments of $10,000 under the Feasibility Study.

The technology involves the use of a Nanometric powder formulation (solid) comprising of a cannabinoid oil and other materials which is dispersed in water controlled by several repeatable parameters. The oil concentration can be increased or decreased in the process and can include permeation enhancers for increasing bioavailability. In addition, it can be formulated in various pharmaceutical delivery systems such as capsules, tablets, creams and aqueous dispersions.

The cannabinoid-based medicinal powders intended to be developed in conjunction with Yissum contain controlled substance (cannabis) as defined in the Israeli Dangerous Drugs Ordinance [New Version], 5733 - 1973. In Israel, licenses to cultivate, possess and to use cannabis for medical research are granted by the Ministry of Health, IMCU - Israel Medical Cannabis Unit, on an ad-hoc basis. On May 2, 2018, Canna Powder Israel also entered into a License Agreement and a Research Agreement with Yissum, copies of which were filed as Exhibits 10.2 and 10.3 to the Form 8-K filed with the SEC on May 25, 2018, as discussed below. Fully-executed copies of the License Agreement and Research Agreement are attached hereto as exhibits 10.2.2 and 10.3.3, respectively.

Pursuant to the License Agreement, our subsidiary was granted an exclusive license to make commercial use of the Licensed Technology (as defined in the License Agreement attached as exhibit 10.2.2 hereto) developed by Prof. Shlomo Magdassi and Dr. Liraz Larush from Casali Center, Institute of Chemistry, The Hebrew University of Jerusalem working in collaboration with Rafi Ezra, CTO of Canna Powder Israel. The License Agreement further provides that Yissum shall retain the right: (i) to make, use and practice the Licensed Technology for the University’s own research and educational purposes; (ii) to license or otherwise convey to other academic and not-for-profit research organizations, the Licensed Technology for use in non-commercial research; and (iii) to license or otherwise convey the Licensed Technology to any third party for research or commercial applications, subject to the terms of the License Agreement, which shall expire, upon the later of: (i) the date of expiration in such country of the last to expire Licensed Patent (as defined in the License Agreement) included in the Licensed Technology; (ii) the date of expiration of any exclusivity on the product granted by a regulatory or government body in such country; or (iii) the end of a period of 20 years from the date of the first commercial sale in such country.

10

The License Agreement further provides as follows:

(a) Upon the expiration of the later of the periods set forth above, the Subsidiary shall have a fully-paid non-exclusive license to the know-how, and shall have an irrevocable option to obtain an exclusive license to the know-how by paying Yissum 50% of the net sales and any sublicense consideration (as defined in the License Agreement);

(b) The License which shall continue for a period of 2 years after termination of the later of the periods as referred to above and shall be renewed automatically for additional successive 2-year periods, unless our Subsidiary or Yissum notifies the other that it does not wish the License to be renewed;

(c) The Subsidiary shall only be entitled to grant a Sublicense after obtaining Yissum’s written approval regarding the identity of the Sublicensee and all material terms and conditions of the Sublicense; and

(d) In consideration for the grant of the License, the Subsidiary shall pay Yissum the royalties at a rate of 4% of net sales; (ii) Sublicense fees at a rate of 20% of sublicense consideration.

Pursuant to the terms of the Research Agreement, the following material provisions apply:

(a) The Research shall commence following the actual written receipt by Yissum of an applicable permit to perform the Research issued by the Israeli Ministry of Health, with prompt notice to the Subsidiary;

(b) The Research will be performed by or under the control and supervision of Professor Shlomo Magdassi;

(c) The Subsidiary shall pay Yissum ten thousand US$10,000 per month, inclusive of overhead in consideration for the performance of the Research.

Government Regulation - United States

The legal cannabis industry in the U.S. has evolved considerably during the past five years and many observers believe that the industry may have reached or may soon reach the point where further legalization in additional states will follow. We believe that this will be as the result of likely growing pressure from citizens’ groups in individual states in the U.S. for the legalization of medical cannabis. At the United States federal level, cannabis is still classified as an illegal substance under the Controlled Substances Act. This classification makes cannabis illegal under federal law to cultivate, manufacture, distribute or possess cannabis, and has created a discrepancy between state’s rights and federal law. It also means that production must be local to consumption as it cannot cross state lines.

Public support has resulted in the passing of new cannabis laws and regulations in a number of countries and 29 states in the U.S.

11

 

Countries world-wide, except perhaps in Latin American and Asia, are already responding to the state-by-state dismantling of prohibition in America by moving to allow medical use (as in Australia, Germany, and Colombia) or to outright legalization (as in Uruguay).

We believe cannabinoid-based drugs using the powders we plan on developing may be able to provide a treatment model for patients suffering from certain diseases, disorders and medical conditions. Nevertheless, at present, because of U.S. FDA and DEA restrictions, most companies involved in research and development of cannabinoid therapeutic applications currently use synthetics and we cannot state when or if this will change. Furthermore, the Company has not yet commenced any preclinical development, filing of an IND, phase I trials, phase II trials, phase III trials, and submission of an NDA, all of which is required by the FDA for drug approval.

To the extent that in the future, we shall seek to be able to conduct some of our research and development relating to our cannabis powders in the United States, we will become subject to the United States’ Federal Controlled Substances Act of 1970 and regulations promulgated thereunder. While cannabis is a Schedule I controlled substance, drugs approved for medical use in the United States that contain cannabis or cannabis extracts must be placed in Schedules II-V, since approval by the FDA satisfies the “accepted medical use” requirement. If any of our drug candidates, if and when developed, of which there can be no assurance, will receive approval by the FDA, such drugs under present regulations and laws must be listed by the Drug Enforcement Agency or DEA as a Schedule II or III controlled substance to be allowed for commercialization. Consequently, the manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use of our future drugs will be subject to a significant degree of regulation by the DEA. In addition, individual states in the United States have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal law because the states are separate jurisdictions, they may separately schedule our drugs.

To the extent that we plan in the future to sell nanometric cannabis powder to product development companies and the creation of our own final cannabis products, we will become subject to applicable Good Manufacturing Practice (“GMP”) regulations on our business and the FDA approval process related to planned final cannabis products. The impact of a GMP certificate on our planned business is very limited as there are many states in the U.S. where a GMP certificate for a Cannabis product is not required and the Company does not limit itself where to operate. The Company has not performed any pre-industrial meeting with the FDA and has not begun to design a clinical trial for its planned products. As a result, the Company cannot determine at present with any certainty the FDA requirements necessary for approval of our planned products if, in fact, we will be in position to seek FDA approval. We understand that prior to scheduling any pre-industrial meeting(s) with the FDA, we will have to have completed product development and designated a candidate clinical indication. At present, it is uncertain if and when this information will be available, if ever.

12

Government Regulation - The European Community

Even though we do not currently intend to conduct research and development in the European Community, we may seek to do so in the future. Approximately 250 substances, including cannabis, are listed in the Schedules annexed to the United Nations Single Convention on Narcotic Drugs (New York, 1961, amended 1972), the Convention on Psychotropic Substances (Vienna, 1971) and the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (introducing control on precursors) (Vienna, 1988). The purpose of these listings is to control and limit the use of these drugs according to a classification of their therapeutic value, risk of abuse and health dangers, and to minimize the diversion of precursor chemicals to illegal drug manufacturers. The 1961 UN Single Convention on Narcotic Drugs, as amended in 1972 classifies cannabis as Schedule I (“substances with addictive properties, presenting a serious risk of abuse”) and as Schedule IV (“the most dangerous substances, already listed in Schedule I, which are particularly harmful and of extremely limited medical or therapeutic value”) narcotic drug. The 1971 UN Convention on Psychotropic Substances classifies THC - the principal psychoactive cannabinoid of cannabis - as a schedule I psychotropic substance (Substances presenting a high-risk of abuse, posing a particularly, serious threat to public health which are of very little or no therapeutic value).

Most countries in Europe are parties to these conventions which govern international trade and domestic control of these substances, including cannabis. They may interpret and implement their obligations in a way that creates a legal obstacle to our obtaining manufacturing and/or marketing approval for our drugs in those countries. These countries may not be willing or able to amend or otherwise modify their laws and regulations to permit our drug candidates to be manufactured and/or marketed or achieving such amendments to the laws and regulations may take a prolonged period. In the European Community, medical cannabis program regulatory frameworks exist in countries, including the Netherlands, Italy, Germany, Finland, Norway, Ukraine, Estonia, Switzerland and the Czech Republic. It is also anticipated that there will be policy changes in many member countries of the European Union regarding the medical use of cannabis and cannabinoid-derived drugs.

Government Regulation - Israel

Because of our intention to develop drugs containing cannabis plant-derived cannabinoids, we will be required to conduct our research and development activities in Israel. The cannabinoid-based drugs we hope and intend to develop, contain controlled substance (cannabis) as defined in the Israeli Dangerous Drugs Ordinance [New Version], 5733 - 1973. In Israel, licenses to cultivate, possess and to use cannabis for medical research are granted by the Ministry of Health, IMCU - Israel Medical Cannabis Unit, on an ad-hoc basis. If we proceed in Israel, we intend to obtain necessary IMCU licenses to carry out our drug development projects. This will require our acquiring the cannabis needed for our research activities from an Israeli government-licensed medical cannabis grower. Because we do not have a license to possess cannabis, the cannabis that will be required for our studies must be transported from the licensed grower directly to our research facilities or those of a contract research organization, in compliance with a license to use cannabis for medical research. If we proceed with research in Israel, we will apply for all necessary licenses needed to conduct our drug development projects. There can be given no assurance that we will obtain all necessary licenses and approvals.

We believe that there will be rising demand for cannabinoid-derived drugs and that future growth is likely to be driven by favorable changes in legislation and demographic factors. Controlled substance laws differ between countries and legislation in certain countries may restrict or limit our ability to distribute our cannabis-based powders, once developed, for us if drugs. Nevertheless, we believe that the U.S. can potentially represent a major market for CannaPowder-based drug candidates.

ITEM 1A. RISK FACTORS

Risks Relating to Our Lack of Operating History and Industry.

Risks Relating to Our Business

Any investment in our shares of common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this annual report before you decide to invest in our common stock. Each of the following risks may materially and adversely affect our business objective, plan of operation and financial condition. These risks may cause the market price of our common stock to decline, which may cause you to lose all or a part of the money you invested in our common stock. We provide the following cautionary discussion of risks, uncertainties and possible inaccurate assumptions relevant to our business plan. In addition to other information included in this annual report, the following factors should be considered in evaluating the Company’s business and future prospects.

13

The Company has a limited operating history and very limited resources.

The Company’s recent operations have been limited and has had no revenues from operations. Investors will have no basis upon which to evaluate the Company’s ability to achieve the Company’s plan of operation.

The Company’s officers and sole director may allocate their time to other businesses thereby causing conflicts of interest in his determination as to how much time to devote to the Company’s affairs. This could have a negative impact on the Company’s ability to implement its plan of operation.

The Company’s two executive officers, Oded Gilboa, our CFO, and Liron Carmel, our CEO and sole director, are not required nor are they expected to commit their full time to the Company’s affairs, which may result in a conflict in allocating their time between the Company’s business and other businesses. Management of the Company is engaged in several other business endeavors and while none of which are involved in the medical cannabis business, they are not precluded by employment or non-competition agreements or otherwise from becoming involved in cannabis related businesses that may compete with the Company, either directly or indirectly. Members of our Management are not obligated to contribute any specific number of hours per week to the Company’s affairs. If Management’s other business affairs require them to devote a substantial amount of time to such other business affairs, it could limit their ability to devote time to the Company’s affairs and could have a negative impact on the Company’s ability to implement its plan of operation.

Mr. Gilboa's other business endeavors include providing financial statement preparation, book and record keeping and financial consulting for a number of small to medium sized businesses in addition to Canna Powder Inc. During the past five years, Mr. Gilboa has provided services to private Israeli companies including: (i) Bootnest Ltd, an Internet service provider with headquarters located in Ra'anana, Israel that identifies, develops and utilizes business opportunities in various fields of interest, with emphasis on business initiatives in the field of sports, among other fields, and provides business consulting and relates services in raising capital; and (ii) Professional Patent Solutions Ltd, engaged in developing technology based and industry-based IP strategies for leading start-ups and established companies in the fields of communication, semiconductors and computing principally in Israel. Mr. Carmel's other business endeavors include providing management and strategic consulting services to a number of small to medium sized businesses and organization including: (i) Board member and consultant to Virtual Crypto Technologies Ltd. a company engaged in technology development to allow fast and accurate cryptocurrencies trade executions (ii) Active chairman of the Israeli Table Tennis Association. (iii) From 2013 – 2017 vice president of the Givatayim city Economic Company.

The Company may be unable to obtain additional financing, if required, to complete its plan of operation or to fund the operations and growth of it business, which could compel the Company to abandon its business.

If we require funds, we will be required to seek additional financing. We cannot assure you that such financing would be available on acceptable terms, if at all. To the extent that additional financing proves to be unavailable when needed, we would be compelled to abandon our business plan. In addition, we may require additional financing to fund the operations or growth of our business. The failure to secure additional financing could have a material adverse effect on the continued development or growth of our business. The Company’s officers, director or stockholders are not required to provide any financing to us.

Broad discretion of Management

Any person who invests in the Company’s common stock will do so without an opportunity to evaluate the specific merits or risks our business. As a result, investors will be entirely dependent on the broad discretion and judgment of Management. There can be no assurance that determinations made by the Company’s Management will permit us to achieve the Company’s business plan.

General Economic Risks.

The Company’s current and future business objectives and plan of operation are likely dependent, in large part, on the state of the general economy. Adverse changes in economic conditions may adversely affect the Company’s business objective and plan of operation. These conditions and other factors beyond the Company’s control include also but are not limited to regulatory changes.

Our control shareholders have significant voting power and may take actions that may be different than actions sought by our other stockholders.

Our control shareholders own approximately 40.2% of the outstanding shares of our common stock. These stockholders will be able to exercise significant influence over all matters requiring stockholder approval. This influence over our affairs might be adverse to the interest of our other stockholders. In addition, this concentration of ownership could delay or prevent a change in control and might have an adverse effect on the market price of our common stock.

14

Our officers and sole director are located in Israel and our assets may also be held from time to time outside of the United States.

Since all of our officers and sole director are currently located in and/or are residents of Israel, any attempt to enforce liabilities upon such individuals under the U.S. federal securities and bankruptcy laws may be difficult. In accordance with the Israeli Law on Enforcement of Foreign Judgments, 5718-1958, and subject to certain time limitations (the application to enforce the judgment must be made within five years of the date of judgment or such other period as might be agreed between Israel and the United States), an Israeli court may declare a foreign civil judgment enforceable if it finds that:

- the judgment was rendered by a court which was, according to the laws of the State in which the court is located, competent to render the judgment;

- the judgment may no longer be appealed;

- the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and

- the judgment is executory in the State in which it was given.

An Israeli court will not declare a foreign judgment enforceable if:

- the judgment was obtained by fraud;

- there is a finding of lack of due process;

- the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;

- the judgment is in conflict with another judgment that was given in the same matter between the same parties and that is still valid; or

- the time the action was instituted in the foreign court, a suit in the same matter and between the same parties was pending before a court or tribunal in Israel.

Furthermore, Israeli courts may not adjudicate a claim based on a violation of U.S. securities laws if the court determines that Israel is not the most appropriate forum in which to bring such a claim. Even if an Israeli court agrees to hear such a claim, it may determine that Israeli law, not U.S. law, is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact, which can be a time-consuming and costly process.

Our assets may also be held from time to time outside of the United States. Since our director and executive officers are foreign citizens and do not reside in the United States, it may be difficult for courts in the United States to obtain jurisdiction over our foreign assets or persons, and as a result, it may be difficult or impossible for you to enforce judgments rendered against us or our sole director or executive officers in United States courts. Thus, investing in us may pose a greater risk because should any situation arise in the future in which you would have a cause of action against these persons or against us, you may face potential difficulties in bringing lawsuits or, if successful, in collecting judgments against these persons or against the Company.

Regulatory Risks

We face risks related to compliance with corporate governance laws and financial reporting standards.

The Sarbanes-Oxley Act of 2002, as well as related new rules and regulations implemented by the Securities and Exchange Commission and the Public Company Accounting Oversight Board, require changes in the corporate governance practices and financial reporting standards for public companies. These new laws, rules and regulations, including compliance with Section 404 of the Sarbanes-Oxley Act of 2002 relating to internal control over financial reporting, have materially increased the legal and financial compliance costs of small companies and have made some activities more time-consuming and more burdensome.

15

We face risks associated with laws and regulations applicable to controlled substances; difficulties of complying with laws that differ from jurisdiction to jurisdiction.

Our planned cannabis powder-based products will contain controlled substances and are subject laws of the U.S. and many foreign countries as well as a myriad of rules and regulations. Controlled substance laws differ, often radically, between countries and from state to state in the United States and legislation in certain countries and states are subject to change, perhaps to our detriment, and, as a result, may restrict or even severely limit our ability to distribute cannabis-based powders, if and when we complete development, of which there can be no assurance. Furthermore, there can be no assurance that we will be able to successfully address the difficulties we expect to confront in efforts to comply with the laws and regulations applicable to cannabis-related medical products in different jurisdictions in which we will seek to operate. These differences, from jurisdiction to jurisdiction and from state to state may be expected to restrict or limit in a material manner our ability to commercially exploit and distribute our products in one or more jurisdictions/states where the regulations or laws are in conflict or are mutually exclusive.

We may not have effective internal controls.

The rules and regulations of the SEC require a public company to prepare and file periodic reports under the Exchange Act, which will require that the Company engage legal, accounting, auditing and other professional service providers. The engagement of such services is costly and continuing. Additionally, the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) requires, among other things, that we design, implement and maintain adequate internal controls and procedures over financial reporting. The costs of complying with the Sarbanes-Oxley Act and the limited technically qualified personnel we have may make it difficult for us to design, implement and maintain adequate internal controls over financial reporting. We expect these costs to be increased as our operations increase in scope and magnitude. In the event that we fail to maintain an effective system of internal controls or discover material weaknesses in our internal controls, we may not be able to produce reliable financial reports and/or discover and report fraud, which may harm our overall financial condition and result in loss of investor confidence and a decline in our share price.

As a public company and the effective date of this registration statement on Form 10 on June 29, 2018, we became subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act of 2010 and other applicable securities rules and regulations. Our legal and financial compliance costs related to these rules and regulations may increase, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual and quarterly, and, from time-to-time, current reports with respect to our business and operating results.

We are working with our legal, independent accounting and financial advisors to identify those areas in which changes should or could be made to improve our financial and management control systems in order to manage our growth and our legal obligations as a public company. These areas include corporate governance, corporate control, disclosure controls and procedures and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas, if and when any perceived deficiencies are discovered. However, we anticipate that the expenses associated with being a reporting public company are expected to be both material and continuing. We estimate that the aggregate cost of legal services; accounting and audit functions; personnel, such as a chief financial officer familiar with the obligations of public company reporting; and consultants to design and implement internal controls could be material. In addition, if and when we retain independent directors and/or additional members of senior management, we may incur additional expenses related to director compensation and/or premiums for directors’ and officers’ liability insurance (“D&O Insurance”), the costs of which we cannot estimate at this time. We may also incur additional expenses associated with investor relations and similar functions, the cost of which we also cannot estimate at this time. However, these additional expenses individually, or in the aggregate, may also be expected to be material. In addition, being a public company could make it more difficult or more-costly for us to obtain certain types of insurance, including D&O Insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

Risks Relating to Operating in Israel.

We conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel or the Middle East.

Our subsidiary offices and our officers and sole director are located in Israel. Accordingly, political, economic and military conditions in Israel and the Middle East may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect our operations and could make it more difficult for us to raise capital. Since September 2000, terrorist violence in Israel has increased significantly and negotiations between Israel and Palestinian representatives have not achieved a peaceful resolution of the conflict. The establishment in 2006 of a government in Gaza by representatives of the Hamas militant group has created additional unrest and uncertainty in the region.

16

Further, Israel is currently engaged in an armed conflict with Hamas, which until Operation Cast Lead in January 2009 had involved thousands of missile-strikes and had disrupted most day-to-day civilian activity in southern Israel. The missile attacks by Hamas did not target Tel Aviv, the location of our principal executive offices; however, any armed conflict, terrorist activity or political instability in the region may negatively affect business conditions and could significantly harm our results of operations.

Risks Related to Our Common Stock

Our historic stock price has been volatile and the future market price for our common stock is likely to continue to be volatile. Further, the limited market for our shares will make our price more volatile. This may make it difficult for you to sell our common stock.

The public market for our common stock has been very volatile. Over the past three fiscal years and subsequent quarterly periods, the market price for our common stock has ranged from $0.35 to $2.70 (See “Market for Common Equity and Related Stockholder Matters” in this annual report). Any future market price for our shares is likely to continue to be very volatile. This price volatility may make it more difficult for you to sell shares when you want at a price you find attractive. Further, the market for our common stock is limited and we cannot assure you that a larger market will ever be developed or maintained. Market fluctuations and volatility, as well as general economic, market and political conditions, could reduce our market price. As a result, this may make it difficult or impossible for you to sell our common stock.

The Company’s shares of common stock are quoted on the OTC Pink Sheet market, which limits the liquidity and price of the Company’s common stock.

The Company’s shares of common stock are traded on the OTC Pink Sheet market. Quotation of the Company’s securities on the OTC Pink Sheet market limits the liquidity and price of the Company’s common stock more than if the Company’s shares of common stock were listed on The Nasdaq Stock Market or a national exchange. There is currently no active trading market in the Company’s common stock. There can be no assurance that there will be an active trading market for the Company’s common stock following a business combination. In the event that an active trading market commences, there can be no assurance as to the market price of the Company’s shares of common stock, whether any trading market will provide liquidity to investors, or whether any trading market will be sustained.

Our common stock is subject to the Penny Stock Rules of the SEC and the trading market in our common stock is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our common stock.

The Securities and Exchange Commission has adopted Rule 3a51-1 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 require:

- that a broker or dealer approve a person’s account for transactions in penny stocks; and

- the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:

- obtain financial information and investment experience objectives of the person; and

- make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

17

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:

- sets forth the basis on which the broker or dealer made the suitability determination; and

- that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

State blue sky registration; potential limitations on resale of the Company’s common stock

The holders of the Company’s shares of common stock registered under the Exchange Act and those persons who desire to purchase them in any trading market that may develop in the future, should be aware that there may be state blue-sky law restrictions upon the ability of investors to resell the Company’s securities. Accordingly, investors should consider the secondary market for the Registrant’s securities to be a limited one.

It is the intention of the Registrant’s Management following the consummation of a business combination to seek coverage and publication of information regarding the Registrant in an accepted publication manual which permits a manual exemption. The manual exemption permits a security to be distributed in a particular state without being registered if the Registrant issuing the security has a listing for that security in a securities manual recognized by the state. However, it is not enough for the security to be listed in a recognized manual. The listing entry must contain (1) the names of issuers, officers, and directors, (2) an issuer’s balance sheet, and (3) a profit and loss statement for either the fiscal year preceding the balance sheet or for the most recent fiscal year of operations. Furthermore, the manual exemption is a non-issuer exemption restricted to secondary trading transactions, making it unavailable for issuers selling newly issued securities.

Most of the accepted manuals are those published by Standard and Poor’s, Moody’s Investor Service, Fitch’s Investment Service, and Best’s Insurance Reports, and many states expressly recognize these manuals. A smaller number of states declare that they “recognize securities manuals” but do not specify the recognized manuals. The following states do not have any provisions and therefore do not expressly recognize the manual exemption: Alabama, Georgia, Illinois, Kentucky, Louisiana, Montana, South Dakota, Tennessee, Vermont and Wisconsin.

Dividends unlikely

The Company does not expect to pay dividends for the foreseeable future because it has no revenues or cash resources. The payment of dividends will be contingent upon the Company’s future revenues and earnings, if any, capital requirements and overall financial conditions. The payment of any future dividends will be within the discretion of the Company’s board of directors as then constituted. It is the Company’s expectation that future management, following a business combination, will determine to retain any earnings for use in its business operations and accordingly, the Company does not anticipate declaring any dividends in the foreseeable future.

18

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND PLAN OF OPERATION

The following Management’s Discussion and Analysis of Financial Condition and Plan of Operations (“MD&A”) is intended to help you understand our historical results of operations during the periods presented and our financial condition. This MD&A should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements and contains forward-looking statements that involve risks and uncertainties. See section entitled “Forward-Looking Statements” above.

Plan of Operation

At present, we are a Company with only limited operations and no revenues from operations. There is substantial doubt that we can continue as an on-going business for the next twelve months, notwithstanding our success in our Equity Raise discussed more fully in this Form 10 amendment.

On August 30, 2017, a 90% owned subsidiary of the Company was registered in Israel under the name of Canna Powder Ltd. (“CannaPowder Israel” or the “Subsidiary”).

Development is being conducted at the Hebrew University pursuant to the term of the Feasibility Study and Option Agreement under the supervision of the inventor of the technology, Professor Shlomo Magdassi.

The Subsidiary’s management includes Lavi Krasney, its CEO, and Rafi Ezra, its CTO. Mr. Krasney has over 20 years of international experience in corporate finance, venture capital and investment banking. He has served as CEO and director of several private companies. Mr. Ezra is a highly experienced pharmacist with extensive knowledge of the cannabis sector and active experience of leading early-stage pharma companies from early-stage development through commercial launch.

The Company has raised $1,226,900 from the issuance and sale of equity securities to fund its development program to establish cannabis powder production facilities utilizing the licensed technology. Reference is made to the disclosure in “Item 10. Recent Sales of Unregistered Securities” below.

Pursuant to the Company’s Development Program, we expect to have product formulation and testing completed in 2020, pre-clinical studies commencing in 2021, first human and safety trials in 2022 and efficacy trials in 2023. As a result, unless we are able to expedite the above timetable, of which there can be no assurance, the earliest that we can expect to begin commercial sales will be 2023. In fact, there can be no assurance that the Development Program will be successfully implemented within our expected timeline notwithstanding the Company’s success in its Equity Raise to date, nor can there be assurance that the Company may not require additional capital to fully implement its business plan and complete production of commercially viable products based on its technology which is the subject of the Feasibility Study discussed below under “Planned Research and Development and Current Trends.” Reference is also made to Appendix B-1 attached to the License Agreement filed as an exhibit to our Form 8-K filed with the SEC on May 25, 2018.

However, there can be no assurance that our expectations will reach fruition or that we will have sufficient capital or other resources to complete our development program in a timely manner, if at all. If and when we achieve the commercial stage, of which there can be no assurance, our plan is for Canna Powder Israel to establish and operate several production facilities, each located in countries and territories selected according to their size and favorable regulatory environment for medical cannabis. Our business plan is to establish the first production facility in Israel. This site will be the Company’s pilot site for all its developments, which is expected to be established before the end of 2019, of which there can be no assurance, and which plan is wholly-dependent on the continued availability of capital resources. We plan is to follow our site with Israel with sites in the U.S. but only in those states where cannabis-based medical products are authorized for medicinal use and/or recreational use. However, at the date of this registration statement on Form 10, we have not yet determined the actual states where we hope to establish production facilities as the legal situation of Cannabis is continuing to evolve in the U.S. The Company also plans to establish a site in Canada and in Germany. In both of these countries, medical cannabis is regulated. Our plan is for our cannabis powder products to be supplied to producers of medical cannabis products. The ability to produce a more effective, consistent product in terms of quality and composition, will hopefully provide us with a competitive advantage when targeting the medical market. However, there can be no assurance that we will be successful in implementing our development program, establishing sites in Israel, the U.S., Canada and/or Germany, or elsewhere, for that matter.

Results of Operations during the three and six months ended June 30, 2018 as compared to the three and six months ended June 30, 2017

During the three and six months ended June 30, 2018 we generated revenues of $0 and $0 as compared three and six months ended June 30, 2017 in which we also generated revenues of $0 and $0, respectively.

19

Our research and development expenses during the three and six months ended June 30, 2018 were $18,069 and $56,881 as compared to the three and six months ended June 30, 2017 in which the research and development expenses were $0 and $0, respectively. The significant increase was due to research and development activities of the new subsidiary.

Our general and administrative expenses during the three and six months ended June 30, 2018 were $170,700 and $237,883, respectively as compared to the three months ended June 30, 2017 in which we had general and administrative income of $3,950 and six months ended June 30, 2017 in which we had general and administrative expenses of 8,827. The significant increase was mostly due to general and administrative expenses in the new subsidiary.

Other expenses during the three and six months ended June 30, 2018 were $0 and $0, respectively compared to $151 and $122, respectively, for the three and six months ended June 30, 2017.

Other expenses of $151 for the six months ended June 30, 2017 were comprised of $203 interest expenses offset by $50 gain from debt settlement during the same period in the prior year, while other expenses of $122 for the three months ended June 30, 2017 were comprised of $172 interest expenses offset by $50 gain from debt settlement.

We incurred a net loss of $188,769 and $294,764, respectively, during the three and six months ended June 30, 2018 compared to $4,072 and $8,980, respectively, during the same periods in the prior year.

Of this amount loss attributable to non-controlling interest for the three and six months ended June 30, 2018 was $7,235 and $15,187, respectively, compared to $0 and $0, respectively, during the same periods in the prior year.

Results of Operations during the year ended December 31, 2017 as compared to the year ended December 31, 2016

During 2017 and 2016 we generated revenues of $0 and $0, respectively. Our general and administrative expense increased to $75,177 during 2017 compared to $2,601 during the same period in prior year and our research and development expenses increased to $10,007 during 2017 compared to $0 during the same period in the prior year both increases were due to costs incurred in relation to our new subsidiary CannaPowder. We incurred a net loss of $85,970 during 2017 compared to a net loss of $2,644 in 2016.

Liquidity and Capital Resources

Our balance sheet as of June 30, 2018 reflects $840,228 in total assets consisting of cash and cash equivalents of $815,058 and prepaid assets of $25,170. As of December 31, 2017, our balance sheet reflects $330,926 in total assets consisting of cash and cash equivalents of $326,730 and prepaid assets of $4,196.

As of June 30, 2018, we had total current liabilities of $800 consisting of accounts payable and accrued liabilities and $800. As of December 31, 2017, we had total current liabilities of $800 consisting of accounts payable and accrued liabilities of $800 and long term liabilities of $2,687 consisting of notes payable.

We had positive working capital of $839,428 as of June 30, 2018 compared to $330,126 at December 31, 2017. Such working capital has been sufficient to sustain our operations to date. Our total liabilities as of June 30, 2018 were $800 compared to $3,487 at December 31, 2017.

During the six months ended June 30, 2018, we used $315,738 in our operating activities. This resulted from a net loss of $279,577 attributable to Canna Powder, Inc. $15,187 loss attributable to non-controlling interest and increase in prepaid expenses of $20,974.

During the six months ended June 30, 2017, we used $11,778 in our operating activities. This resulted from a net loss of $8,980 and increase to accounts payable of $2,748.

During the six months ended June 30, 2018, we financed our negative cash flow by financing activities through sale of common stock in the amount of $813,900 offset by payments to notes payable of $2,687.

During the six months ended June 30, 2017, we financed our negative cash flow by financing activities through issuance of notes payable of $11,778.

Our balance sheet as of December 31, 2017 reflects $330,926 in total assets consisting of cash and cash equivalents of $326,730 and prepaid assets of $4,196. As of December 31, 2016, our balance sheet reflects assets of $0.

20

As of December 31, 2017, we had total current liabilities of $800 consisting of accounts payable and accrued liabilities and $2,687 of long term liabilities consisting of notes payable. As of December 31, 2016, we had total current liabilities of $2,144 consisting of accounts payable and $800 of long term liabilities consisting of notes payable.

We had positive working capital of $330,126 as of December 31, 2017 compared to negative working capital of $2,144 at December 31, 2016. Such working capital has been sufficient to sustain our operations to date. Our total liabilities as of December 31, 2017 were $3,487 compared to $2,944 at December 31, 2016.

During 2017, we used $91,560 in our operating activities. This resulted from a net loss of $85,970, decrease to accounts payable and accrued expenses of $1,344 decrease in prepaid expenses of $4,196 and gain on settlement of $50.

During 2016, we used $800 in our operating activities. This resulted from a net loss of $2,644 offset by an increase to accounts payable and accrued expenses of $1,844.

During the year ended December 31, 2017, we financed our negative cash flow from sale of common stock in the amount of $413,000, borrowings on debt of $19,190 which were offset by principal payment on debt of $17,253.

During the year ended December 31, 2016, we financed our negative cash flow from borrowings on debt of $800.

While management of the Company believes that the Company will be successful in its current and planned operating activities, there can be no assurance that the Company will be successful in the achievement of sales of its products that will generate sufficient revenues to earn a profit and sustain the operations of the Company.

Our ability to create sufficient working capital to sustain us over the next twelve-month period, and beyond, is dependent on our entering into additional licensing agreement and on our success in issuing additional debt or equity or entering into strategic arrangement with a third party. There can be no assurance that sufficient capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

Going Concern Consideration

There is substantial doubt about our ability to continue as a going concern. Our financial statements contain additional note disclosures with respect to this matter.

The Company currently plans to satisfy its cash requirements for the next 12 months through the issuance of equity and borrowings from its controlling shareholders and believes it can satisfy its cash requirements so long as it is able to obtain financing from its controlling shareholders. The Company expects that money borrowed will be used during the next 12 months to satisfy the Company’s operating costs, professional fees and for general corporate purposes.

The Company has only limited capital. Additional financing is necessary for the Company to continue as a going concern. Our independent auditor has issued an unqualified audit opinion for the years ended December 31, 2017 and 2016 with an explanatory paragraph on going concern.

Off-Balance Sheet Arrangements

As of December 31, 2017, and 2016, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.

Contractual Obligations and Commitments

As of December 31, 2017, and 2016, we did not have any contractual obligations.

21

Critical Accounting Policies

Our significant accounting policies are described in the notes to our financial statements for the years ended December 31, 2017 and 2016 and are included elsewhere in this annual report.

ITEM 3. PROPERTIES

Our office facilities are located at 20 Raoul Wallenberg Street, Tel Aviv, Israel, consisting of 1200 square feet at a base monthly rent of $500. These offices are leased from an entity related to Attribute Ltd (See Item 4 below) which rent represents the fair market value of the facilities. The Company believes that its facilities are sufficient for the foreseeable future and until we actively commence our sales and marketing efforts. At such time, we believe that adequate facilities will be available for our Subsidiary’s operations at terms satisfactory to the Company.

ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the beneficial ownership of our common stock as of April 20, 2018. The information in this table provides the ownership information for: each person known by us to be the beneficial owner of more than 5% of our common stock; each of our directors; each of our executive officers; and our executive officers and directors as a group.

Name of Beneficial Owner	Common Stock Beneficially Owned (1)		Percentage of Common Stock Owned (1)
Attribute Ltd(2)		787,500		7.9	%
20 Raoul Wallenberg Street
Tel Aviv, Israel
Kfir Silberman and L.I.A. Pure Capital (entity controlled by Kfir Silberman)		787,500		7.9	%
3 Ha’armonim St.,
Ramat Gan, Israel
Amir Uziel		787,500		7.9	%
5 Shira St Street
Rishon Lezion, Israel
Lavi Krasney, CEO of CannaPowder Ltd		787,500		7.9	%
8 Paamoni Street
Rishon Lezion, Israel
Liron Carmel, CEO and Chairman		300,000		3.0	%
20 Raoul Wallenberg Street
Tel Aviv, Israel
Oded Gilboa, CFO		0		0.00
20 Raoul Wallenberg Street
Tel Aviv, Israel
Total Officers and Directors (2 people)		300,000		3.4	%

22

(1) Applicable percentage ownership is based on 9,948,077 shares of common stock issued as of August 7, 2018. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock that are currently exercisable or exercisable within 60 days of April 20, 2018 are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage of ownership of such person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

(2) Itschak Shrem, a resident of Israel, is the control person of and is the natural person with voting and dispositive power over the shares held by Attribute Ltd.

ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS; KEY EMPLOYEES

Our sole director hold office until the next annual general meeting of the stockholders or until his/their successors are elected and qualified. Our officers are appointed by our Board of Directors and hold office until the earlier of their death, retirement, resignation, or removal.

The following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held by each.

Name	Age	Title
Liron Carmel	34	CEO and sole director
Oded Gilboa	45	CFO

Liron Carmel, 34. Chief Executive Officer and Sole Director: Mr. Carmel has been the Company’s CEO and sole director since December 2014 and served as its CFO from December. From December 2014 to August 2015, Mr. Carmel was the CEO and CFO of Zaxis International Inc., now known as Virtual Crypto Technologies, Inc. (OTCQB: VRCP). From 2010 through December 2014, Mr. Carmel served as a senior analyst in the Investment Division of Excellence Group, a leading investment firm in Israel. In such capacity, Mr. Carmel specialized in risk management and special debt financing including participation in and leading negotiations with major institutional investors in Israel. From 2009 to 2010, Mr. Carmel was an analytical consultant for Precise Group, an Israeli financial institution.

Oded Gilboa, 45, Chief Financial Officer: was appointed to be the Company’s CFO on January 1, 2018. He is a licensed CPA in the United States and Israel. He was the CFO of TechCare Corp. (OTCQB: TECR) from December 2013 to October 2016. Prior to his appointment as CFO of TechCare Corp., Mr. Gilboa served as TechCare’s finance and accounting consultant. Mr. Gilboa has over 16 years of experience in finance and public accounting, having served as a senior finance executive in the technology and biotech industries with responsibilities in corporate finance, accounting, strategic planning and operational and financial management. From 2010 through 2012, Mr. Gilboa served as the Revenue Accounting and Finance Manager of Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), a global company focused on the development, manufacturing and marketing of prescription drug products. From 2007 through 2009, Mr. Gilboa was the Executive director of Finance and US Controller of Taro Pharmaceuticals (NASDAQ: TAROF), a global pharmaceutical company. From 1998 through 2007 Mr. Gilboa held various financial positions with IDT Corporation (NYSE: IDT), a world-wide provider of telecommunications and media services, where in his most recent role he served as director of Finance. Mr. Gilboa began his career in public accounting, auditing both public and private companies and holds a B.A in Economics and Accounting from Tel-Aviv University and an M.B.A. from Recanati Business School at Tel-Aviv University.

23

Key Employees

Rafi Ezra, age 47, Chief Technology Officer, Canna Powder Ltd: Mr. Ezra was appointed as CTO of the Company’s Israeli subsidiary, Canna Powder Ltd in December 2017, has over 20 years’ experience in the bio-med industry and as a clinical pharmacist with broad knowledge of pharmacology, from science to production. Since 2003, Mr. Ezra has been the CEO of Annette Ezra Ltd, an Israeli pharmaceutical consulting firm that has been actively involved in research of Medical Cannabis. From 2016 to 2018, he was CEO and Chief Pharmacist at Lipicare Pharmaceuticals, a subsidiary of Bio-LightIsraeli Life Sciences Investments Ltd., a public company listed on the Tel Aviv Stock Exchange (BOLT: TASE), engaged in R&D of Nano-technology ophthalmology products and the management of outsourced development teams. From 2007 to 2014, Mr. Ezra served as CEO and Chief Pharmacist at More Biofix Ltd, an Israeli company engaged in the development of dermato-technology to remove skin lesions and tissue preservation, during which he was responsible for clinical trials, regulatory approvals and locating partners and investors. Since 2000, Mr. Ezra has been a member of the board of The Pharmaceutical Association of Israel, served as Head of Strategic Planning. He also served as a director of Sharam Pharm, a pharmacy with over 100 branches in Israel.

Rafi Ezra holds an M.Sc. in Clinical Pharmacy from Hebrew University of Jerusalem and B.Sc. in Pharmacy from Brighton University in England.

Lavi Krasney, age 51, CEO of Canna Powder Ltd: Mr. Krasney has over 20 years of international experience in corporate finance, venture capital and investment banking. He has served as CEO and director of several private companies and since February 2018, Mr. Krasney has been a member of the Board of Directors of Pimi Agro Ltd., an Israeli subsidiary of Save Foods, Inc. (OTCPK: SAFO), a public company in the process of becoming a reporting company under the OTC and thereafter under the Exchange Act. Since 1998 he has been CEO and principal of CapitaLink Ltd, an Israeli economic consulting firm and has been a portfolio manager with approximately US$450 million under his management. He started his career at Bank Hapoalim and served in the Intelligence Corp. of the Israeli Army. Mr. Krasney holds a BA in Economics from the University of Haifa and an MBA in Finance from Tel Aviv University.

Committees of the Board of Directors

We do not presently have a separately constituted audit committee, compensation committee, nominating committee, executive committee or any other committees of our Board of directors. As such, our entire Board of directors acts as our audit committee.

Involvement in Legal Proceedings

None of our directors, nominees for directors, or officers has appeared as a party during the past ten years in any legal proceedings that may bear on his ability or integrity to serve as a director or officer of the Company.

Code of Ethics

The Company has adopted a code of ethics applicable to our principal, executive and financial officers.

24

Potential Conflict of Interest

Since we do not have an audit or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our Board of directors. Thus, there is a potential conflict of interest in that our directors have the authority to determine issues concerning management compensation, in essence their own, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executives or directors.

Board’s Role in Risk Oversight

The Board assesses on an ongoing basis the risks faced by the Company. These risks include financial, technological, competitive, and operational risks. The Board dedicates time at each of its meetings to review and consider the relevant risks faced by the Company at that time. In addition, since the Company does not have an Audit Committee, the Board is also responsible for the assessment and oversight of the Company’s financial risk exposures.

ITEM 6. EXECUTIVE COMPENSATION

The following table sets forth information concerning the total compensation that we have paid or that has accrued on behalf of our chief executive officer and other executive officers with annual compensation exceeding $100,000 during the fiscal years ending December 31, 2017, 2016 and 2015.

								Long Term
		Annual Compensation						Compensation Awards
						Other		Restricted		Securities
						Annual		Stock		Underlying		All Other
		Salary		Bonus		Compensation		Award(s)		Options		Compensation
Name and Principal Position	Year	($)		($)		($)		($)		($)		($)
Liron Carmel, CEO, and Director (1)	2017		15,000		-		-		-		-		-
	2016		-		-		-		-		-		-
	2015		-		-		-		-		-		-
Oded Gilboa, CFO (1)	2017		-		-		-		-		-		-
	2016		-		-		-		-		-		-
	2015		-		-		-		-		-		-

We do not currently have a stock option plan. No individual grants of stock options, whether or not in tandem with stock appreciation rights known as SARs or freestanding SARs have been made to any executive officer or any director since our inception; accordingly, no stock options have been granted or exercised by any of the officers or directors since we were founded.

Long-Term Incentive Plans and Awards

We do not have any long-term incentive plans that provide compensation intended to serve as incentive for performance. No individual grants or agreements regarding future payouts under non-stock price-based plans have been made to any executive officer or any director or any employee or consultant since our inception; accordingly, no future payouts under non-stock price-based plans or agreements have been granted or entered into or exercised by any of the officers or directors or employees or consultants since we were founded.

Compensation of Directors

There are no current agreements pursuant to which directors are or will be compensated in the future for any services provided as a director.

Employment Contracts, Termination of Employment, Change-in-Control Arrangements

There are no employment contracts in place, no employees were terminated and no change in control arrangements have been signed with the Company.

25

ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

During the years ended December 31, 2017 and 2016, the Company issued the following restricted securities to affiliated purchasers, including: Itschak Shrem, through his entity, Attribute Ltd; Kfir Silberman and his entity, L.I.A. Pure Capital Ltd; Amir Uziel and Lavi Krasney, who is also CEO of Canna Powder Israel.

On October 17, 2017, the Company issued and sold a total of 2.6 million restricted shares of common stock to four accredited investors (650,000 shares to each) at $0.01 per share for a total cash consideration of $26,000. Reference is made to Item 4. Security Ownership of Certain Beneficial Owners and Management. As a result of these issuances, the four accredited investors became greater than 5% shareholders.

ITEM 8. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against our Company, nor of any proceedings that a governmental authority is contemplating against us. We know of no material proceedings to which any of our directors, officers, affiliates, owner of record or beneficially of more than 5 percent of our voting securities or security holders is an adverse party or has a material interest adverse to our interest.

ITEM 9. MARKET FOR REGISTRANT’S COMMON STOCK AND RELATED STOCKHOLDER MATTER

Market Information

Our common stock is quoted on the OTC Pink Sheets Market under the symbol SMGY, an inter-dealer automated quotation system for equity securities not included on The Nasdaq Stock Market. Quotation of the Company’s securities on the OTC Pink Sheets Market limits the liquidity and price of the Company’s common stock more than if the Company’s shares of common stock were listed on The Nasdaq Stock Market or a national exchange. For the periods indicated, the following table sets forth the high and low bid prices per share of common stock. The below prices represent inter-dealer quotations without retail markup, markdown, or commission and may not necessarily represent actual transactions.

	Price Range
Period	High		Low
Year Ended December 31, 2015:
First Quarter	$	2.70	$	1.01
Second Quarter	$	2.69	$	0.99
Third Quarter	$	0.99	$	0.86
Fourth Quarter	$	0.75	$	0.60
Year Ended December 31, 2016:
First Quarter	$	0.48	$	0.35
Second Quarter	$	0.35	$	0.35
Third Quarter	$	0.35	$	0.35
Fourth Quarter	$	0.35	$	0.35
Year Ending December 31, 2017:
First Quarter	$	1.00	$	0.35
Second Quarter	$	0.51	$	0.51
Third Quarter	$	1.00	$	0.51
Fourth Quarter	$	0.62	$	0.51
Year Ending December 31, 2018:
First Quarter	$	1.50	$	0.52
Second Quarter	$	1.00	$	0.05

Our stock transfer agent is Transfer Online, Inc., with offices located at 512 SE Salmon Street, Portland, OR 97214. Their phone number is (503) 227-2950 and email address is: info@transferonline.com.

26

Holders. As of June 30, 2018, there 217 registered stockholders holding had 9,948,077 Common Stock.

Dividends. We have never declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. We expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.

Equity Compensation Plans. We do not have any equity compensation plans.

ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES

During the years ended December 31, 2016 and 2015, the Company did not sell any unregistered securities.

Sales of Unregistered Securities in 2017:

On October 17, 2017, the Company sold 6,300,000 shares to 13 shareholders, each an “accredited investor” as that term is defined in Rule 501 of Regulation D promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Act”), for $0.01 a share for a total cash consideration of $63,000.

On October 24, 2017, the Company issued 666,667 shares to one shareholder at $0.075 per share for cash consideration of $50,000.

Between November 15, 2017 and December 7, 2017, the Company sold a total of 1,000,000 units for cash consideration of $300,000 at price of $.30 (the “Units”), each unit comprised of one share of common stock and one class A warrant exercisable at $0.50 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $132,458 for the common stock and $167,542 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of approximately 163% and discount rates ranging from 1.68% to 1.8%.

Sales of unregistered securities in 2018:

Between March 20, 2018 and March 29, 2018, the Company sold a total of 206,000 units for cash consideration of $123,600 at price of $.60 (the “Units”), each unit comprised of one share of common stock and one class B warrant exercisable at $1.20 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $44,454 for the common stock and $79,146 for the class B Warrants.

Between April 3, 2018 and May 14, 2018, the Company sold a total of 1,150,500 units for cash consideration of $690,300 at price of $.60 (the “Units”), each unit comprised of one share of common stock and one class B warrant exercisable at $1.20 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $290,996 for the common stock and $399,304 for the class B Warrants.

On June 30, 2018 and December 31, 2017 there were approximately 217 and 189 holders of record and 9,948,077 and 8,591,577 of the Company’s common stock authorized with $0.00001 par value, respectively. All common shares are entitled to one vote per share in all matters submitted to the shareholders. No preferred shares are issued and outstanding at June 30, 2018 and December 31, 2017.

As discussed above, the Company is continuing to raise capital through the private sale of its equity securities, primarily pursuant to the exemptions provided under Regulation S and to a lesser extent pursuant to Regulation D, both promulgated by the SEC under the Act. To date, the Company has raised approximately $888,775 in the Equity Raise.

The Company believes that the issuances and sale of the restricted securities were exempt from registration pursuant to Section 4(2) of the Act and Regulation S and Regulation D promulgated by the SEC under the Act, as privately negotiated, isolated, non-recurring transactions with accredited investors not involving any public solicitation. The subscribers, in each case, represented to the Company their intention to acquire the securities for investment only and not with a view to the distribution thereof. Appropriate restrictive legends are affixed to the stock certificates issued in such transactions. All recipients of restricted securities represented by the shares of Common Stock and the Units either received adequate information about the Company or had access, through employment, relation and/or business relationships with the Company to such information and each of the subscribers is an accredited investor.

ITEM 11. DESCRIPTION OF REGISTRANT’S SECURITIES TO BE REGISTERED

Common Stock

We are authorized to issue 495,000,000 shares of common stock with a par value of 0$.00001 per share (“Common Stock”). As of August 8, 2018, 9,948,077 shares of our Common Stock were issued and on record with our transfer agent, Transfer Online Inc. Some of the shares of Common Stock issuable in connection with the Company’s Equity Raise have not been yet been issued but are pending issuance.

27

Each outstanding share of Common Stock that is on record with our transfer agent is entitled to one vote, either in person or by proxy, on all matters that may be voted upon by the owners thereof at meetings of the stockholders.

Our shareholders have no pre-emptive rights to acquire additional shares of Common Stock. The Common Stock is not subject to redemption or any sinking fund provision, and it carries no subscription or conversion rights. In the event of our liquidation, the holders of the Common Stock will be entitled to share equally in the corporate assets after satisfaction of all liabilities.

The description contained in this section does not purport to be complete. Reference is made to our certificate of incorporation and bylaws which are available for inspection upon proper notice at our offices, as well as to the Nevada Revised Statutes for a more complete description covering the rights and liabilities of shareholders.

Holders of our Common Stock

(i)	have equal ratable rights to dividends from funds legally available therefore, if declared by our Board of Directors,
(ii)	are entitled to share ratably in all our assets available for distribution to holders of Common Stock upon our liquidation, dissolution or winding up;
(iii)	do not have preemptive, subscription or conversion rights or redemption or sinking fund provisions; and
(iv)	are entitled to one non-cumulative vote per share on all matters on which stockholders may vote at all meetings of our stockholders.

28

The holders of shares of our Common Stock do not have cumulative voting rights, which means that the holders of more than fifty percent (50%) of outstanding shares voting for the election of directors can elect all of our directors if they so choose and, in such event, the holders of the remaining shares will not be able to elect any of our directors.

Preferred Stock

The Company’s Articles of Incorporation, as amended, authorize 5,000,000 shares of preferred stock, par value $0.00001 per share, which may be issued by the Board of Directors from time to time in one or more series. Our Board of Directors, without further approval of our stockholders, is authorized to fix the dividend rights and terms, conversion rights, voting rights, redemption rights, liquidation preferences and other rights and restrictions relating to any series of preferred stock that may be issued in the future. Issuances of shares of preferred stock, while providing flexibility in connection with possible financings, acquisitions and other corporate purposes, could, among other things, adversely affect the voting power of the holders of our Common Stock and prior series of preferred stock then outstanding.

Dividends

We have no history of paying dividends, moreover, there is no assurance that we will pay dividends in the future.

Shares Eligible for Future Sale

Our shares are thinly traded on the OTC Market, and we cannot assure you that a significant public market for our Common Stock will be developed. Sales of substantial amounts of Common Stock in the public market, or the possibility of substantial sales occurring, could adversely affect prevailing market prices for our Common Stock or our future ability to raise capital through an offering of equity securities.

As of August 8, 2018, 9,910,381 shares of Common Stock of the total 9,948,077 issued and outstanding shares of Common Stock are “restricted” shares as that term is defined under the Act. We have not entered into any agreement to register any of our issued and outstanding shares, although such agreement may be entered into in the future, or such an agreement may be made part of the terms of a future equity raise or other transactions.

29

ITEM 12. INDEMNIFICATION OF DIRECTORS AND OFFICERS

Our bylaws and articles of incorporation provide that our officers and directors are indemnified to the fullest extent provided by the Nevada Revised Statutes (“NRS”).

Under the Nevada Revised Statutes, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company’s Articles of Incorporation. Our Articles of Incorporation do not specifically limit the directors’ immunity. The NRS excepts from that immunity (a) a willful failure to deal fairly with the company or its shareholders in connection with a matter in which the director has a material conflict of interest; (b) a violation of criminal law, unless the director had reasonable cause to believe that his or her conduct was lawful or no reasonable cause to believe that his or her conduct was unlawful; (c) a transaction from which the director derived an improper personal profit; and (d) willful misconduct.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

The Company has not purchased insurance for the directors and officers that would provide coverage for their acts as an officer or director of the Company.

ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMNTARY DATA

ITEM 14. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS

30

INDEX TO FINANCIAL STATEMENTS

Balance Sheet as of June 30, 2018 (Unaudited)	F-1
Statement of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2017 and 2018 (Unaudited)	F-2
Statement of Cash Flows for the Six Months Ended June 30, 2017 and 2018 (Unaudited)	F-4
Notes to Financial Statements (Unaudited)	F-5
Report of Independent Registered Public Accounting Firm	F-11
Financial Statements for the Years Ended December 31, 2017 and 2016	F-12
Balance Sheets	F-12
Statements of Operations	F-13
Statements of Comprehensive Income (Loss)	F-14
Statement of Stockholders’ Deficit	F-15
Statements of Cash Flows	F-16
Notes to Financial Statements	F-17

31

Canna Powder, Inc.

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2018 AND DECEMBER 31, 2017

(unaudited)

	June 30, 2018			December 31, 2017
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	815,058		$	326,730
Prepaid expenses		25,170			4,196
Total current assets		840,228			330,926
Total assets	$	840,228		$	330,926
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	800		$	800
Total current liabilities		800			800
Notes payable	$	-		$	2,687
Total long term liabilities		-			2,687
Total liabilities	$	800		$	3,487
Stockholders’ equity
Common stock, par value $0.00001 per share, 495,000,000 common shares authorized, 5,000,000 preferred shares authorized; 9,948,077 and 8,591,577 shares issued and outstanding at June 30, 2018 and December 31, 2017 respectively.	$	99		$	86
Accumulated other comprehensive income		(3,794	)		3,353
Non-controlling interest		(15,187	)		-
Additional paid in capital		1,261,051			447,164
Accumulated deficit		(402,741	)		(123,164	)
Total stockholders’ equity		839,428			327,439
Total liabilities and stockholders’ equity	$	840,228		$	330,926

The accompanying notes are an integral part of these financial statements

F-1

Canna Powder, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017

(unaudited)

	For the three months ended						For the six months ended
	June 30, 2018			June 30, 2017			June 30, 2018			June 30, 2017
Revenues	$	-		$	-		$	-		$	-
Expenses:
Research and Development expenses		(18,069	)		-			(56,881	)		-
G&A Expenses		(170,700	)		3,950			(237,883	)		(8,827	)
Total operating expenses		(188,769	)		(3,950	)		(294,764	)		(8,827	)
(Loss) from operations		(188,769	)		(3,950	)		(294,764	)		(8,827	)
Other income (expense):
Gain (loss) from debt settlement		-			50			-			50
Interest expense		-			(172	)		-			(203	)
Other income (expense)		-			(122	)		-			(151	)
Provision for income taxes		-			-			-			-
Net (loss)		(188,769	)		(4,072	)		(294,764	)		(8,980	)
Less: loss (income) attributable to non-controlling Interest		7,235			-			15,187			-
Net (loss) attributable to Canna Powder, Inc.		(181,534	)		(4,072	)		(279,577	)		(8,980	)
Loss per share		(0.02	)		(0.01	)		(0.03	)		(0.01	)
Weighted average shares outstanding Basic and diluted		9,549,255			624,910			9,080,605			624,910

The accompanying notes are an integral part of these financial statements.

F-2

Canna Powder, Inc.

STATEMENTS OF COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017

(unaudited)

	For the three months ended						For the six months ended
	June 30, 2018			June 30, 2017			June 30, 2018			June 30, 2017
Net loss		(188,769	)		(4,072	)		(294,764	)		(8,980	)
Change in unrealized foreign currency translation gain (loss)		(3,665	)		-			(7,147	)		-
Total comprehensive loss		(192,434	)		(4,072	)		(301,911	)		(8,980	)
Less: comprehensive loss attributable to non-controlling interest		7,235			-			15,187			-
Comprehensive loss attributable to Canna Powder, Inc.		(185,199	)		(4,072	)		(286,724	)		(8,980	)

The accompanying notes are an integral part of these financial statements.

F-3

Canna Powder, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2018 and 2017

(unaudited)

	For the six months			For the six months
	ended			ended
	June 30, 2018			June 30, 2017
Operating Activities:
Net (loss) attributable to Canna Powder, Inc.	$	(279,577	)	$	(8,980	)
Non –controlling interest in loss of consolidated subsidiary		(15,187	)		-
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Changes in net assets and liabilities:
Decrease (increase) in prepaid expenses		(20,974	)		-
Decrease (increase) in gain on settlement of notes payable		-			(50	)
(Decrease) increase in accounts payable		-			(2,748	)
Net Cash used in operating activities		(315,738	)		(11,778	)
Financing Activities:
Debt and principal payments on debt		(2,687	)		-
Issuance of non -convertible notes		-			11,778
Proceeds from sale of common stock (net of issuance expenses)		813,900			-
Net Cash provided by financing activities		811,213			11,778
FX Adjustment		(7,147	)
Net increase (decrease) in cash		488,328			-
Cash and cash equivalents - beginning of period	$	326,730		$	-
Cash and cash equivalents - end of period	$	815,058		$	-

The accompanying notes are an integral part of these financial statements.

F-4

CANNA POWDER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note (1) Summary of Significant Accounting Policies

Basis of Presentation and Organization

The Company was incorporated in 1999 in the state of Utah under the name Datigen.com, Inc. On August 25, 2005, the Company changed its state of incorporation from Utah to Nevada by the merger of the Company with and into its wholly-owned subsidiary, Canna Powder, Inc., a Nevada corporation. As a result of such merger, the Company’s name was changed to Canna Powder, Inc. in order to better reflect the Company’s business operations.

On August 30, 2017, a new wholly-owned subsidiary was registered in Israel under the name of Canna Powder Ltd. (“CannaPowder Israel” or the “Subsidiary”), with 100 common shares outstanding, 0.01 NIS par value (the “Subsidiary Shares”), all of which were held in escrow on behalf of the Company by Israel attorney, Alon Nave. On September 27, 2017, pursuant to board resolution, the 100 Subsidiary Shares held in escrow were transferred to the Company.

On December 27, 2017, a board-resolution was adopted to issue an additional: (i) 800 Subsidiary Shares to the Company; and an additional 100 Subsidiary Shares to Rafi Ezra and, as a result, effective December 27, 2017, Canna Powder Ltd became a 90% owned subsidiary of the Company and a minority interest of 10% owned by Rafi Ezra.

The Subsidiary’s management includes Lavi Krasney, its CEO, and Rafi Ezra, its CTO. Mr. Krasney has over 20 years of international experience in corporate finance, venture capital and investment banking. He has served as CEO and director of several private companies. Mr. Ezra is a highly experienced pharmacist with extensive knowledge of the cannabis sector and active experience of leading early-stage pharma companies from early-stage development through commercial launch.

Development is being conducted at the Hebrew University pursuant to the term of the Feasibility Study and Option Agreement under the supervision of the inventor of the technology, Professor Shlomo Magdassi.

The Company reasonably expects that the Development Program will be completed within three years, with commercial sales starting in 2021, however there can be no assurance that the Development Program will, in fact, be successful. Notwithstanding the Company’s success in its Equity Raise to date, nor can there be assurance that the Company may not require additional capital to fully implement its business plan and complete production of commercially viable products based on its technology which is the subject of the Feasibility Study discussed below under “Planned Research and Development and Current Trends.”

In the commercial stage, the Company’s plan is to establish and operate several production facilities, each located in separate territories determined by the Company according to their size and regulatory environment that permits studies applicable to other activities prerequisite to commercial exploitation of medical cannabis generally and the Company’s plan to develop cannabis-based powders for medical uses. While there can be no assurance, at present the Company believes that it will be able to produce cannabis powders for medical uses at a significant cost advantage.

The accompanying unaudited financial statements of the Company are presented in accordance with the requirements of Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for an air presentation have been made. The results for these interim periods are not necessarily indicative of the results for the entire year. The accompanying financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017 and the notes thereto included in the Company’s Report on Form 10-K12G filed with the SEC on April 30, 2018.

F-5

Cash and Cash Equivalents

For purposes of reporting within the statement of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents. As of June 30, 2018, and December 31, 2017, we had cash and cash equivalents of $815,058 and $326,730 respectively.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.

Discontinued Operations

The Company follows the policy of segregating the assets and liabilities of subsidiaries or lines of business on its Balance Sheet from the assets liabilities of continuing subsidiaries or lines of businesses when it is decided to close or dispose of a subsidiary or line of business. The Company also, follows the policy of separately disclosing the assets and liabilities and the net operations of a subsidiary or line of business in its financial statements when it is decided to close or dispose of a subsidiary or line of business.

Revenue Recognition

The Company recognizes revenue ratably over the term of the contract in accordance with ASC 606. In 2018, we are implementing new internal controls as part of our efforts to adopt the new revenue recognition standard. These internal controls include providing global training to our finance team and holding regular meetings with management and the Audit Committee to review and approve key decisions. Upon adoption, we expect to implement new internal controls related to our accounting policies and procedures. We will require new internal controls to address risks associated with applying the five-step model, specifically related to judgments made in connection to variable consideration and applying the constraint. Additionally, we will establish monitoring controls to identify new sales arrangements and changes in our business environment that could impact our current accounting assessment. During the second half of 2018, we expect to finalize our impact assessment and redesign impacted processes, policies and controls.

Loss per Common Share

Basic loss per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the period. Fully diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about the realizability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Fair Value of Financial Instruments

The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts the Company could realize in a current market exchange. As of June 30, 2018 and December 31 2017, the carrying value of accounts payable and accrued liabilities approximated fair value due to the short-term nature and maturity of these instruments.

F-6

Deferred Offering Costs

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.

Impairment of Long-Lived Assets

The Company evaluates the recoverability of long-lived assets and the related estimated remaining lives when events or circumstances lead management to believe that the carrying value of an asset may not be recoverable. As of December 31, 2017, no events or circumstances occurred for which an evaluation of the recoverability of long-lived assets was required.

Estimates

The financial statements are prepared on the basis of accounting principles generally accepted in the United States. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of June 30, 2018 and December 31, 2017, and expenses for the six months ended June 30, 2018 and 2017. Actual results could differ from those estimates made by management.

Impact of Recently Issued Accounting Standards

In June 2018, the FASB issued Accounting Standards Update, or ASU 2018-07, Compensation - Stock Compensation (Topic 718), which simplifies the accounting for non-employee share-based payment transactions. The new standard expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018 (including interim periods within that fiscal year), with early adoption permitted. The Company adopted the new standard in the second quarter of 2018 and determined that the application of the new standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2018.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. Public business entities should apply the amendments in this Update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019.

In March 2017, the FASB issued Update 2017-08—Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities.For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

In March 2017, the FASB issued Update 2017-07—Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. Effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those annual periods. For other entities, the amendments in this Update are effective for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. Early adoption is permitted as of the beginning of an annual period for which financial statements (interim or annual) have not been issued or made available for issuance. That is, early adoption should be within the first interim period if an employer issues interim financial statement. Disclosures of the nature of and reason for the change in accounting principle are required in the first interim and annual periods of adoption.

F-7

Goodwill and Intangible Assets

Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the reporting unit’s carrying value is compared to its fair value. The fair values of the reporting units are estimated using market and discounted cash flow approaches. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. The discounted cash flow approach uses expected future operating results. Failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit.

Intangible assets consist of patents and trademarks, purchased customer contracts, purchased customer and merchant relationships, purchased trade names, purchased technology, and non-compete agreements. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from two to twenty years. No significant residual value is estimated for intangible assets.

Note (2) Going Concern

The Company has limited operations. The Company was previously engaged in activities including efforts to develop and market its Battery Brain technology, which efforts ceased during the quarter ended September 30, 2009. On August 30, 2017, the Company formed a subsidiary in Israel under the name of Canna Powder Ltd (“Canna Israel” or the “Subsidiary”) which is 90% owned by the Company and the remaining 10% is owned by Rafi Ezra, co-founder and CTO of Canna Powder Ltd. The Subsidiary commenced efforts to develop the formulation and process to produce medical products using new technology involving nano-powder derived from cannabis oil. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not yet generated any revenue to cover its operating costs, and as such, has incurred an operating loss since inception. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Note (3) Prepaid expenses

Prepaid expenses repaid expenses of $25,170 at June 30, 2018 and $4,196 at December 31, 2017, consist of VAT paid to be refunded from the Israel VAT authority.

Note (4) Common Stock

On October 17, 2017, the Company sold a total of 6,300,000 shares to 13 shareholders at $0.01 per share for a total cash consideration of $63,000. Four of the shareholders are related parties.

On October 24, 2017 the Company issued 666,667 shares to 1 shareholder at $0.075 per share for cash consideration of $50,000.

Between November 15, 2017 and December 7, 2017, the Company sold a total of 1,000,000 units for cash consideration of $300,000 at price of $.30 (the “Units”), each unit comprised of one share of common stock and one class A warrant exercisable at $0.50 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $132,458 for the common stock and $167,542 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of approximately 163% and discount rates ranging from 1.68% to 1.8%.

Between March 20, 2018 and March 29, 2018, the Company sold a total of 206,000 units for cash consideration of $123,600 at price of $.60 (the “Units”), each unit comprised of one share of common stock and one class B warrant exercisable at $1.20 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $44,454 for the common stock and $79,146 for the class B Warrants.

F-8

Between April 3, 2018 and May 14, 2018, the Company sold a total of 1,150,500 units for cash consideration of $690,300 at price of $.60 (the “Units”), each unit comprised of one share of common stock and one class B warrant exercisable at $1.20 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $290,996 for the common stock and $399,304 for the class B Warrants.

On June 30, 2018 and December 31, 2017 there were approximately 217 and 189 holders of record and 9,948,077 and 8,591,577 of the Company’s common stock authorized with $0.00001 par value, respectively. All common shares are entitled to one vote per share in all matters submitted to the shareholders. No preferred shares are issued and outstanding at June 30, 2018 and December 31, 2017.

Dividends

The Company has not declared or paid any cash dividends on its common stock nor does it anticipate paying any in the foreseeable future. Furthermore, the Company expects to retain any future earnings to finance its operations and expansion. The payment of cash dividends in the future will be at the discretion of its Board of Directors and will depend upon its earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.

Securities Authorized for Issuance under Equity Compensation Plans – None.

Following is a table of warrant and options still outstanding and exercisable along with exercise price and range of remaining term.

Type	Quantity		Exercise Price		Remaining Term
Warrants Class A		1,000,000	$	0.50	18 Months
Warrants Class B		1,356,500	$	1.20	18-24 Months
Total		2,356,500

Note (5) Income Taxes

The Company had deferred income tax assets as of June 30, 2018 and December 31, 2017 as follows:

	June 30, 2018			2017
Loss carryforwards	$	84,576		$	43,107
Less- Valuation allowance		(84,576	)		(43,107	)
Total net deferred tax assets	$	-		$	-

The Company provided a valuation allowance equal to the deferred income tax assets for the period ended June 30, 2018 and December 31, 2017, because it is not presently known whether future taxable income will be sufficient to utilize the loss carryforwards.

F-9

As of June 30, 2018, and December 31, 2017, the Company had approximately $402,741 and $123,164, respectively, in tax loss carryforwards that can be utilized in future periods to reduce taxable income, and expire by the year 2030.

The Company did not identify any material uncertain tax positions that will be filed. The Company did not recognize any interest or penalties for unrecognized tax benefits during the year ended June 30, 2018 and December 31, 2017.

The Company intends to file income tax returns in the United States. All tax years are closed by expiration of the statute of limitations.

Note (6) Related Party Transactions

On October 17, 2017 the issuer’s control persons, Amir Uziel, Attribute Ltd, Lavi Krasney and Kfir Silberman (controlling shareholder of L.I.A. Pure Capital Ltd) purchased 650,000 additional shares each, or 2,600,000 total shares at $0.01 per share for a total cash consideration of $26,000.

On May 1, 2018 a services agreement was signed with an entity controlled by a related party.

Between January 8, 2017 and August 25, 2017 three shareholders loaned the Company amounts totaling $16,403 in loans bearing 8% interest which have no maturity dates. The loans which accrued interest of $879 were repaid on December 20, 2017. The three debt holders confirmed they were owed no principal or interest as of December 31, 2017.

Note (7) Notes Payable

During the year ended December 31, 2017, the Company borrowed $100 and $800, respectively, which the loans bear an interest rate of 8% and has no maturity date. The loans were repaid in the amount of $850 on May 5, 2017 and the Company recorded a gain on debt extinguishment of $50.

On May 12, 2016 a shareholder loaned the Company the sum of $5,000 to settle a vendor debt. The shareholder has subsequently forgiven the debt resulting from this payment and has confirmed he is owed no principal or interest as of December 31, 2016 and December 31, 2017. As of December 31, 2016, the amount paid by the shareholder to the vendor was forgiven, as the shareholder is a related party the forgiven debt resulted in an increase to additional paid in capital.

Between January 8, 2017 and August 25, 2017 three shareholders loaned the Company amounts totaling $16,403 in loans bearing 8% interest which have no maturity dates. The loans which accrued interest of $879 were repaid on December 20, 2017. The three debt holders confirmed they were owed no principal or interest as of December 31, 2017.

On December 22, 2017 a loan was made in the amount $2,687 the loan bears no interest and has no maturity date. The loan which accrued interest of $0 was repaid in full on January 8, 2018

Note (8) Subsequent Events

As defined in FASB ASC 855-10, “Subsequent Events”, subsequent events are events or transactions that occur after the balance sheet date but before financial statements are issued or available to be issued.

The Company evaluated all transactions and events that occurred subsequent to the balance sheet date and prior to the date on which the financial statements contained in this report were issued and determined that no such events or transactions necessitated disclosure.

F-10

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and
Stockholders of Smart Energy Solutions, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Smart Energy Solutions, Inc. (the Company) as of December 31, 2017 and 2016, and the related statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2017 and 2016, and the related notes and schedules (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2017 and 2016, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ M&K CPAS, PLLC

We have served as the Company’s auditor since 2013.

Houston, TX

March 5, 2018

F-11

SMART ENERGY SOLUTIONS, INC.

BALANCE SHEETS

AS OF DECEMBER 31, 2017 AND DECEMBER 31, 2016

	December 31, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	326,730		$	-
Prepaid expenses		4,196			-
Total current assets		330,926			-
Total assets	$	330,926		$	-
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued liabilities	$	800		$	2,144
Total current liabilities		800			2,144
Notes payable		2,687			800
Total long term liabilities		2,687			800
Total liabilities		3,487			2,944
Stockholders’ equity (deficit)
Common stock, par value $0.00001 per share, 495,000,000 common shares authorized, 5,000,000 preferred shares authorized; 8,591,577 and 624,910 common stock issued and outstanding at December 31, 2017 and December 31, 2016 respectively.		86			6
Additional paid in capital		447,164			34,244
Accumulated other comprehensive income		3,353			-
Accumulated deficit		(123,164	)		(37,194	)
Total stockholders’ (deficit)		327,439			(2,944	)
Total liabilities and stockholders’ equity (deficit)	$	330,926		$	-

The accompanying notes are an integral part of these financial statements

F-12

SMART ENERGY SOLUTIONS, INC.

STATEMENTS OF OPERATIONS

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2017 AND 2016

	For the twelve months ended December 31, 2017			For the twelve months ended December 31, 2016
Revenues	$	-		$	-
Expenses:
General and administrative		(75,177	)		(2,601	)
Research and development expense		(10,007	)		-
Total operating expenses		(85,184	)		(2,601	)
(Loss) from operations		(85,184	)		(2,601	)
Gain (loss) from debt settlement		50			-
Interest expense		(836	)		(43	)
Other income (expense)		(786	)		(43	)
Provision for income taxes		-			-
Net (loss)	$	(85,970	)	$	(2,644	)
Net loss per common share	$	(0.01	)	$	(0.00	)
Weighted average number of common shares outstanding		8,591,577			624,910

The accompanying notes are an integral part of these financial statements.

F-13

SMART ENERGY SOLUTIONS, INC.

STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

FOR THE YEARS ENDED DECEMBER 31, 2017 AND 2016

	For the twelve months ended
	December 31, 2017			December 31, 2016
Net loss from continuing operations		(85,970	)		(2,644	)
Change in unrealized foreign currency translation gain (loss)		3,353			-
Total comprehensive loss		(82,617	)		(2,644	)
Comprehensive loss attributable to Smart Energy Solutions, Inc		(82,617	)		(2,644	)

The accompanying notes are an integral part of these financial statements.

F-14

SMART ENERGY SOLUTIONS, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT)

FOR THE YEARS DECEMBER 31, 2017 AND 2016

	Common stock				Additional Paid-In		Other Comprehensive		Accumulated
	Shares		Amount		Capital		Income		Deficit			Totals
Balance as of December 31, 2015		624,910	$	6	$	34,244	$	-	$	(34,550	)	$	(300	)
		-				-		-		-			-
Net loss for the year ended December 31, 2016		-		-		-		-		(2,644	)		(2,644	)
Balance as of December 31, 2016		624,910		6		34,244		-		(37,194	)		(2,944	)
Shares Issued for Cash		7,966,667		80		412,920		-		-			413,000
Translation adjustments		-		-		-		3,353		-			3,353
Net loss for the year ended December 31, 2017		-		-		-		-		(85,970	)		(85,970	)
Balance as of December 31, 2017		8,591,577	$	86	$	447,164	$	3,353	$	(123,164	)	$	327,439

The accompanying notes are an integral part of these financial statements.

F-15

SMART ENERGY SOLUTIONS, INC.

STATEMENTS OF CASH FLOWS

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2017 and 2016

	For the twelve months ended December 31, 2017			For the twelve months ended December 31, 2016
Operating Activities:
Net loss	$	(85,970	)	$	(2,644	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on settlement		(50	)		-
Changes in operating assets and liabilities:
Increase (decrease) in accounts payable and accrued expenses		(1,344	)		1,844
Decrease (decrease) in prepaid expenses		(4,196	)		-
Net cash used in operating activities		(91,560	)		(800	)
Investing Activities:
Purchase of property and equipment		-			-
Net Cash provided by (used in) investing activities		-			-
Financing Activities:
Shares issued for cash		413,000			-
Borrowings on debt		19,190			800
Principal payments on debt		(17,253	)		-
Net cash provided by financing activities		414,937			800
Foreign currency adjustment		3,353
Net increase (decrease) in cash		326,730			-
Cash and cash equivalents - beginning of period	$	-		$	-
Cash and cash equivalents - end of period	$	326,730		$	-

The accompanying notes are an integral part of these financial statements.

F-16

SMART ENERGY SOLUTIONS, INC.

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2017 and 2016

Note (1) Summary of Significant Accounting Policies

Basis of Presentation and Organization

The Company was incorporated in 1999 in the state of Utah under the name Datigen.com, Inc. On August 25, 2005, the Company changed its state of incorporation from Utah to Nevada by the merger of the Company with and into its wholly-owned subsidiary, Canna Powder, Inc., a Nevada corporation. As a result of such merger, the Company’s name was changed to Canna Powder, Inc. in order to better reflect the Company’s business operations.

On August 30, 2017, a new wholly-owned subsidiary was registered in Israel under the name of Canna Powder Ltd. (“CannaPowder Israel” or the “Subsidiary”), with 100 common shares outstanding, 0.01 NIS par value (the “Subsidiary Shares”), all of which were held in escrow on behalf of the Company by Israel attorney, Alon Nave. On September 27, 2017, pursuant to board resolution, the 100 Subsidiary Shares held in escrow were transferred to the Company.

On December 27, 2017, a board-resolution was adopted to issue an additional: (i) 800 Subsidiary Shares to the Company; and an additional 100 Subsidiary Shares to Rafi Ezra and, as a result, effective December 27, 2017, Canna Powder Ltd became a 90% owned subsidiary of the Company and a minority interest of 10% owned by Rafi Ezra.

The Subsidiary’s management includes Lavi Krasney, its CEO, and Rafi Ezra, its CTO. Mr. Krasney has over 20 years of international experience in corporate finance, venture capital and investment banking. He has served as CEO and director of several private companies. Mr. Ezra is a highly experienced pharmacist with extensive knowledge of the cannabis sector and active experience of leading early-stage pharma companies from early-stage development through commercial launch.

Development is being conducted at the Hebrew University pursuant to the term of the Feasibility Study and Option Agreement under the supervision of the inventor of the technology, Professor Shlomo Magdassi.

The Company reasonably expects that the Development Program will be completed within three years, with commercial sales starting in 2021, however there can be no assurance that the Development Program will, in fact, be successful. Notwithstanding the Company’s success in its Equity Raise to date, nor can there be assurance that the Company may not require additional capital to fully implement its business plan and complete production of commercially viable products based on its technology which is the subject of the Feasibility Study discussed below under “Planned Research and Development and Current Trends.”

The accompanying financials statement of the Company were prepared from the account of the Company under the accrual basis of accounting.

Cash and Cash Equivalents

For purposes of reporting within the statement of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents. As of December 31, 2017 and 2016, we had cash and cash equivalents of $326,730 and $0, respectively.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.

Discontinued Operations

The Company follows the policy of segregating the assets and liabilities of subsidiaries or lines of business on its Balance Sheet from the assets liabilities of continuing subsidiaries or lines of businesses when it is decided to close or dispose of a subsidiary or line of business. The Company also, follows the policy of separately disclosing the assets and liabilities and the net operations of a subsidiary or line of business in its financial statements when it is decided to close or dispose of a subsidiary or line of business.

F-17

Revenue Recognition

The Company recognizes revenue from licensing its software to customers for contractually defined periods of time. The Company recognizes revenue ratably over the term of the contract in accordance with ASC 605 (1) when the price is fixed and determinable, (2) persuasive evidence of an arrangement exists, (3) delivery has occurred or services have been provided, and (4) collectability is assured.

Loss per Common Share

Basic loss per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the period. Fully diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about the realizability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Fair Value of Financial Instruments

The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts the Company could realize in a current market exchange. As of December 31, 2017, and 2016, the carrying value of accounts payable and accrued liabilities approximated fair value due to the short-term nature and maturity of these instruments.

Deferred Offering Costs

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.

Impairment of Long-Lived Assets

The Company evaluates the recoverability of long-lived assets and the related estimated remaining lives when events or circumstances lead management to believe that the carrying value of an asset may not be recoverable. As of December 31, 2017, no events or circumstances occurred for which an evaluation of the recoverability of long-lived assets was required.

F-18

Estimates

The financial statements are prepared on the basis of accounting principles generally accepted in the United States. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of December 31, 2017 and 2016, and expenses for the years ended December 31, 2017 and 2016. Actual results could differ from those estimates made by management.

Impact of Recently Issued Accounting Standards

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. Public business entities should apply the amendments in this Update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019.

In March 2017, the FASB issued Update 2017-08—Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities.For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period.

In March 2017, the FASB issued Update 2017-07—Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. Effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those annual periods. For other entities, the amendments in this Update are effective for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. Early adoption is permitted as of the beginning of an annual period for which financial statements (interim or annual) have not been issued or made available for issuance. That is, early adoption should be within the first interim period if an employer issues interim financial statements. Disclosures of the nature of and reason for the change in accounting principle are required in the first interim and annual periods of adoption.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities should apply the guidance in ASU 2016-15 to annual reporting periods beginning on December 15, 2017. For all other entities, the guidance in ASU 2016-15 should be applied to annual reporting periods beginning December 15, 2018 and interim periods within fiscal years beginning after December 15, 2019. Earlier application is permitted including interim reporting periods.

Goodwill and Intangible Assets

Goodwill is tested for impairment at a minimum on an annual basis. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the reporting unit’s carrying value is compared to its fair value. The fair values of the reporting units are estimated using market and discounted cash flow approaches. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its fair value. The discounted cash flow approach uses expected future operating results. Failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit.

Intangible assets consist of patents and trademarks, purchased customer contracts, purchased customer and merchant relationships, purchased trade names, purchased technology, and non-compete agreements. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from two to twenty years. No significant residual value is estimated for intangible assets.

F-19

Note (2) Going Concern

The Company was incorporated in 1999 in the state of Utah under the name Datigen.com, Inc. On August 25, 2005, the Company changed its state of incorporation from Utah to Nevada by the merger of the Company with and into its wholly-owned subsidiary, Smart Energy Solutions, Inc., a Nevada corporation. As a result of such merger, the Company’s name was changed to Smart Energy Solutions, Inc. in order to better reflect the Company’s business operations at that time, which involved efforts to develop and market its Battery Brain technology, which efforts ceased during the quarter ended September 30, 2009.

On August 30, 2017, the Company formed a subsidiary in Israel under the name of Canna Powder Ltd, which is 90% owned by Canna Powder, Inc. with the remaining 10% held by Rafi Ezra, co-founder and CTO of Canna Powder Ltd, and commenced efforts to develop the formulation and the production process to produce medical products using new technology involving nano-powder derived from cannabis oil.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not yet generated any revenue to cover its operating costs, and as such, has incurred an operating loss since inception. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company has been raising equity capital to finance its development program in order to establish cannabis powder production facilities utilizing the licensed technology from Yissum under the License Agreement. Pursuant to the Company’s Development Program, we expect to have product formulation and testing completed in 2020, pre-clinical studies commencing in 2021, first human and safety trials in 2022 and efficacy trials in 2023. As a result, unless we are able to expedite the above timetable, of which there can be no assurance, the earliest that we can expect to begin commercial sales will be 2023. In fact, there can be no assurance that the Development Program will be successfully implemented within our expected timeline notwithstanding the Company’s success in its Equity Raise to date, nor can there be assurance that the Company may not require additional capital to fully implement its business plan and complete production of commercially viable products based on its technology which is the subject of the Feasibility Study discussed below under “Planned Research and Development and Current Trends.” Reference is also made to Appendix B-1 attached to the License Agreement filed as an exhibit to our Form 8-K filed with the SEC on May 25, 2018.

If and when we reach the commercial stage, of which there can be no assurance, we intend to establish and operate several production facilities, each located in individual territories selected according to their size and favorable regulation for medical cannabis. The Company believes that with its new facilities it will be able to produce cannabis powders at a significant cost advantage.

Products will be supplied to producers of medical cannabis products. The ability to produce a more effective, consistent product in terms of quality and composition will provide an important advantage when targeting the medical market. The Company has limited operations. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Note (3) Common Stock

On October 17, 2017, the Company sold a total of 6,300,000 shares to thirteen accredited investors at $0.01 per share for a total cash consideration of $63,000.

On October 24, 2017 the Company issued 666,667 shares to one shareholder, an accredited investor, at $0.075 per share or cash consideration of $50,000.

Between November 15, 2017 and December 7, 2017, the Company sold a total of 1,000,000 units for cash consideration of $300,000 at price of $.30 (the “$0.30 Units”), each unit comprised of one share of common stock and one class A warrant exercisable at $0.50 per share with a term of 24 months. The relative fair value of the stock with embedded warrants was $132,458 for the common stock and $167,542 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of approximately 163% and discount rates ranging from 1.68% to 1.8%.

At December 31, 2017 and December 31, 2016, there were approximately 189 and 168 holders of record and 8,591,577 and 624,910 shares of common stock issued and outstanding, respectively. All shares of common stock are entitled to one vote per share in all matters submitted to the shareholders. No preferred shares are issued and outstanding at December 31, 2017 and 2016.

F-20

Dividends

The Company has not declared or paid any cash dividends on its common stock nor does it anticipate paying any in the foreseeable future. Furthermore, the Company expects to retain any future earnings to finance its operations and expansion. The payment of cash dividends in the future will be at the discretion of its Board of Directors and will depend upon its earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.

Securities Authorized for Issuance under Equity Compensation Plans

None

Following is a table of warrant and options still outstanding and exercisable along with exercise price and range of remaining term.

Type	Quantity		Exercise Price		Remaining Term
Warrants Class A		1,000,000	$	0.50	24 Months
Total		1,000,000

(4) Income Taxes

The provision (benefit) for income taxes for the year ended December 31, 2017 and 2016, was as follows (assuming a 35% effective tax rate):

	2017		2016
Current tax provision:
Federal-
Taxable income	$	-	$	-
Total current tax provision	$	-	$	-

The Company had deferred income tax assets as of December 31, 2017 and 2016 as follows:

	2017			2016
Loss carryforwards	$	43,107		$	13,018
Less- Valuation allowance		(43,107	)		(13,018	)
Total net deferred tax assets	$	-		$	-

The Company provided a valuation allowance equal to the deferred income tax assets for the year ended December 31, 2017 and 2016, because it is not presently known whether future taxable income will be sufficient to utilize the loss carryforwards.

As of December 31, 2017 and 2016, the Company had approximately $123,164 and $37,194, respectively, in tax loss carryforwards that can be utilized in future periods to reduce taxable income, and expire by the year 2030.

The Company did not identify any material uncertain tax positions that will be filed. The Company did not recognize any interest or penalties for unrecognized tax benefits during the year ended December 31, 2017 and 2016.

The Company intends to file income tax returns in the United States. All tax years are closed by expiration of the statute of limitations.

Note (5) Related Party Transactions

On October 17, 2017, the Company issued and sold a total of 2.6 million restricted shares of common stock to four accredited investors (650,000 shares to each) at $0.01 per share for a total cash consideration of $26,000. Reference is made to Item 4. Security Ownership of Certain Beneficial Owners and Management. As a result of these issuances, the four accredited investors became greater than 5% shareholders.

F-21

Note (6) Notes Payable

During the year ended December 31, 2017, the Company borrowed $100 and $800, respectively, which the loans bear an interest rate of 8% and has no maturity date. The loans were repaid in the amount of $850 on May 5, 2017 and the Company recorded a gain on debt extinguishment of $50.

On May 12, 2016 a shareholder loaned the Company the sum of $5,000 to settle a vendor debt. The shareholder has subsequently forgiven the debt resulting from this payment and has confirmed he is owed no principal or interest as of December 31, 2016 and December 31, 2017. As of December 31, 2016, the amount paid by the shareholder to the vendor was forgiven, as the shareholder is a related party the forgiven debt resulted in an increase to additional paid in capital.

On December 22, 2017 a loan was made in the amount $2,687 the loan bears no interest and has no maturity date.

Between January 8, 2017 and August 25, 2017 three shareholders loaned the Company amounts totaling $16,403 in loans bearing 8% interest which have no maturity dates. The loans which accrued interest of $879 were repaid on December 20, 2017. The three debt holders confirmed they were owed no principal or interest as of December 31, 2017.

Note (7) Subsequent Events

As defined in FASB ASC 855-10, “Subsequent Events”, subsequent events are events or transactions that occur after the balance sheet date but before financial statements are issued or available to be issued.

The loan made to the Company on December 22, 2017 in the amount $2,687 was repaid on January 8, 2018.

During the period from March 20, 2018 to April 17, 2018, the Company sold a total of 793,000 units to accredited investors for aggregate cash consideration of $475,775 at a price of $0.60 per unit (the “$0.60 Units”), each consisting of: (i) one share of Common Stock; (ii) one class A warrant exercisable at $0.60 per share with a term of 24 months (the “Class A Warrants”); and (ii) one class B warrant exercisable at $1.20 per share with a term of 24 months (the “Class B Warrants”). In connection with the sale of the $0.60 Units, a total of 234,000 shares of Common Stock have been issued to date and an additional 559,000 shares of Common Stock are pending issuance by the transfer agent but have not yet been issued.

The Company evaluated all other events and transactions that occurred subsequent to the balance sheet date and prior to the date on which the financial statements contained in this report were issued, and the Company determined that no such events or transactions necessitated disclosure.

F-22

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) The following documents are filed as exhibits to this report on Form 10-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.	Description
3.1.1	Articles of Incorporation of the Company filed as an exhibit to the Company’s Form 10-SB on May 11, 1999.
3.1.2	Certificate of Amendment for the Name Change to CannaPowder, Inc. dated December 11, 2017, filed with the Company’s Form 10-12G/A on July 3, 2018
3.1.3	Certificate of Organization of Canna Powder Ltd. dated August 30, 2017 filed with the State of Israel, filed herewith.
3.2.1	By-laws of the Registrant, filed with the Company’s Form 10-12G/A on July 3, 2018
10.1.2	Feasibility Study and Option Agreement dated September 14, 2017 [fully-executed], filed herewith.
10.2.2	License Agreement with Yissum dated May 2, 2018 [fully-executed], filed herewith.
10.3.2	Research Agreement with Yissum dated May 2, 2018 [fully-executed], filed herewith.
31.1	Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form 10/12GA to be signed on its behalf by the undersigned.

CannaPowder, Inc.

By:	/s/ Liron Carmel
	Liron Carmel
	Chief Executive Officer and Chairman
	(Principal Executive Officer)
Date: September 24, 2018
By:	/s/ Oded Gilboa
	Oded Gilboa
	Chief Financial Officer
	(Principal Executive Officer)
Date: September 24, 2018

33